Page 11234..10..»

Archive for the ‘Hypogonadism’ Category

Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr… – UroToday

Testicular cancer is one of the most curable solid malignancies, even in advanced stages. However, the high cure rate among testicular cancer survivors (TCS) is offset by the long-term toxicity of oncologic treatments which include second malignant neoplasms, hypogonadism, pulmonary toxicity, and nephrotoxicity. Compared to the normal population, TCS have an increased risk of dying from circulatory diseases and infections. Such risk is particularly greater in patients who received chemotherapy.1

Elderly people are at high risk of developing cancer and have a decreased ability to control infections. These complications are greatly caused by immunosenescence, the aging process of the immune system. Immunosenescence is characterized by several changes in the lymphocyte subpopulations: there is a decrease in T cells and nave lymphocytes (B and T cells), while CD57+ and CD28- terminally differentiated senescent cells increase. The cell-cycle regulating protein p16INK4a is also a senescence biomarker; its expression in most tissues increases with cellular aging.2

Cytotoxic chemotherapy can induce cellular senescence in normal and cancer cells.3 Therefore, we hypothesized that TCS have premature immunosenescence, which may explain the aforementioned long-term complications. This pilot study aimed to search for lymphocyte senescence surface markers as well as p16INK4a gene expression among TCS who were given chemotherapy.4

Our team conducted a case-control study of TCS matched by age and gender with healthy controls. We included patients with at least threebleomycin, etoposide, and cisplatin (BEP) chemotherapy cycles and no evidence of disease for at least three months. Patients with high-dose chemotherapy were excluded. Peripheral blood mononuclear cells were isolated and lymphocyte subpopulations were analyzed by flow cytometry. B and T cells and their corresponding nave and memory subpopulations were defined according to their surface marker combinations. p16INK4a gene expression in T cells was measured using quantitative polymerase chain reaction.

We found that TCS who had previously received chemotherapeutic agents had statistically significant lower levels of total T cells and CD4+ T cells. Among the CD4+ T lymphocytes, TCS had less nave and increased effector memory cells. Within the CD8+ T lymphocytes, TCS exhibited a decrease in the percentage of nave cells and an increase in CD45RA + CD57+ cells (surface markers related to the later stages of differentiation). Furthermore, we found that there was a statistically significant higher p16INK4a gene expression in TCS as compared to the matched controls. These differences are highlighted in Figure 1.

Figure 1.Immunosenescence profile of testicular cancer survivors (TCS) compared with healthy controls.

Our data suggest that TCS previously treated with chemotherapy may have an immunological phenotype associated with immunosenescence. Potential confounders for these results (like diabetes and hypogonadism) were controlled and excluded. Chemotherapys causal effect, however, remains to be defined. Our study has several limitations, the most important being the cross-sectional nature of it, and we do not know if these alterations persist over time. Future evaluations are necessary to be done in a longitudinal study that allows a patients evaluation at diagnosis, during, and after oncologictreatments.

We believe that further studies are required to help elucidate the clinical implications of the premature immunosenescence in TCS. This is a group of patients that warrants special attention for they receive oncologic treatments at a very young age, and premature immunosenescence may impose many consequences during their lifespan.

Written by: Maria T Bourlon, MD, MSc, Twitter:@BourlonMaite, Francisco J Castro-Alonso, MD, Arturo Carballo, MD, Luis Llorente, MD, Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn, Mexico City, Mexico

References:

Read more:
Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday

Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News – Jumbo News

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

To remain ahead of your competitors, request for a sample[emailprotected]https://www.persistencemarketresearch.com/samples/29509

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

To receive Methodology request here @https://www.persistencemarketresearch.com/methodology/29509

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region. In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

To receive extensive list of important regions, Request Table of content here @https://www.persistencemarketresearch.com/toc/29509

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith

About Us

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping business ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact Us:

Persistence Market Research (PMR)

Address 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales [emailprotected]

Continued here:
Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News

The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy’s Hockey Law – Murphy’s Hockey Law

According to Persistence Market Researchs new report,globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceedUS$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

https://murphyshockeylaw.net/

Read more:
The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law

Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha… – UroToday

Fatigue is one of the most common adverse events of systemic therapy in patients with metastatic renal cell carcinoma (RCC). The aim of multicenter randomized phase 2 study was to determine the efficacy and safety of testosterone in patients with fatigue developed during targeted therapy.

Male patients with metastatic clear-cell RCC, normal prostate-specific antigen level, low testosterone level, and no evidence of hypothyroidism receiving first-line sunitinib or pazopanib with fatigue were randomly assigned (1:1) to either testosterone undecanoate (1000mg) and targeted therapy or targeted therapy alone. The primary endpoint was the mean change of fatigue from baseline to 28 days according to the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary endpoints were safety, Functional Assessment of Cancer Therapy-Kidney Symptom Index 19, testosterone serum concentrations, red blood cell count, and hemoglobin level.

Sixty patients were assigned to receive testosterone and targeted therapy (N=30) or targeted therapy alone (N=30). As of the data cutoff on December 30, 2019, median follow-up was 18.2 months. The study achieved its primary endpoint based on the significant differences at day 28 favoring testosterone over targeted therapy alone regarding the decreased level of fatigue (difference between groups, 22.5 points; 95% confidence interval, 18.4-26.6; P=0.012). Significant changes in scores demonstrating the enhanced quality of life with testosterone compared with targeted therapy were also observed for Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 disease-related symptoms (P=0.01). There were nonsignificant differences in red blood cell count and hemoglobin level between the 2 groups (all P>0.05).

Male patients with metastatic RCC and hypogonadism receiving testosterone had less fatigue and better symptom control during targeted therapy.

American journal of clinical oncology. 2021 Jan 27 [Epub ahead of print]

Ilya Tsimafeyeu, Yulia Tishova, Ruslan Zukov, Pavel Borisov, Anastasia Bondarenko, Kristina Zakurdaeva

Kidney Cancer Research Bureau Institute of Oncology, Hadassah Medical Moscow RUDN University I.M. Sechenov First Moscow State Medical University RakFond, Moscow V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk City Clinical Oncology Center, St. Petersburg, Russia.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33512910

Originally posted here:
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday

Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX…

RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone deficiency, today announced that it has appointed Himanshu H. Shah and Shalin Shah as co-CEOs to drive the next phase of growth as the company looks to a potential launch of KYZATREX in Q4 2021 and further the development of Marius deep clinical pipeline.

Himanshu H. Shah brings over 30 years of experience across global capital markets and will continue his role as chairman of the board in addition to co-CEO. He has advised numerous public and private companies over the past decades to help them unlock substantial shareholder value and execute both innovative and pragmatic business strategies.

I am proud to continue serving Marius and work on developing the best treatment options for men with hypogonadism, a common but not widely discussed disease among patients and prescribers, said Himanshu H. Shah, chairman and co-CEO of Marius Pharmaceuticals. Misconceptions about hypogonadism are having a huge impact on the health of millions of men globally and costing the U.S. healthcare system alone billions of dollars annually. There is a huge opportunity for Marius to address these issues and drastically alter the testosterone therapy landscape.

Shalin Shah will also step into the role of co-CEO from chief financial officer and executive vice president of strategy for Marius. Shalin has been integral in driving overall strategy at Marius for the past four years and will oversee the growth of the team and execution of innovative models as it expands both clinically and commercially to become a leading pharmaceutical company.

I am excited for the opportunity to serve Marius in this new capacity, especially at a time when the world is seeing technology and healthcare intersect more than ever, truly helping patients, said Shalin Shah, co-CEO of Marius Pharmaceuticals. I am confident in Marius mission to better the lives of patients by ensuring adequate levels of testosterone and enhance patient care through disruptive technologies and personalization.

Om Dhingra, Ph.D., led the company from initial development of the lead compound through two successful Phase 3 clinical trials and will move into the role of vice chairman. He will help guide the companys clinical development plan and ensure KYZATREX and its differentiating safety and efficacy data is well known in the medical world.

It has been my great pleasure serving the company as CEO. I am very proud of the data we have generated, which we believe will position KYZATREX as the standard of care for patients suffering from hypogonadism globally, said Dr. Om Dhingra, vice chairman of Marius Pharmaceuticals.

If approved by the FDA, KYZATREX has the potential to become the new standard of care for treating patients with hypogonadism. Testosterone is a crucial hormone that is essential to sexual and reproductive health, but also has important functions in metabolic, inflammatory, cardiovascular and neurological health. In the U.S. there are at least six million symptomatic men suffering from hypogonadism, and over 100 million men globally. The resulting medical costs associated with men with untreated hypogonadism and related comorbidities are more than $25 billion in the U.S. alone. Current treatments on the market are dominated by therapies with unappealing administration methods, including auto-injections, in-office infusions and topical gels and creams that have a high transference risk. KYZATREX is an orally administered treatment that avoids the drawbacks that keep men from continuing treatment on available testosterone therapies.

About KYZATREX KYZATREX if approved, will represent a novel oral testosterone replacement therapy option for adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

The ReTUNE study was a multi-center, 12-month study across the U.S. that studied the safety and efficacy of KYZATREX in hypogonadal subjects (total testosterone 281 ng/dL). Efficacy was determined by number of subjects in the normal, eugonadal range after 90 days of treatment, including dose titrations, while safety was monitored for a further 9 months while on a steady dose. In addition to testosterone parameters, the study collected Patient Reported Outcomes (PROs), which showed statistically significant results both from baseline and against its comparator. A pivotal six-month Phase 3 study was conducted, in which subjects were monitored using ABPM, now considered the standard BP assessment by the FDA and clinical experts. An improved dose regimen was also used in the pivotal six-month Phase 3 study. The results of the Phase 3 studies will be published in leading medical journals and presented at national conferences in 2021.

The FDA has conditionally accepted KYZATREX as the trade name for this investigational drug. The safety and efficacy have not been fully evaluated by any regulatory authority.

About Marius PharmaceuticalsMarius is a specialty pharmaceutical company focusing on treating conditions that are primarily associated with hypogonadism, commonly referred to as testosterone deficiency. The companys mission is to improve the functional lives of patients and reduce the risks of the downstream effects of endocrine imbalance by ensuring appropriate level of testosterone. For more information, please visit http://www.mariuspharma.com.

Media Contact: Emily Brice919-610-3319ebrice@fwv-us.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f825d70b-874a-4cef-9160-429f83bbfc66

https://www.globenewswire.com/NewsRoom/AttachmentNg/ba2569ca-0922-4b49-8d68-49424b5e44d4

Himanshu H. Shah

Co-CEO and Chairman of the Board, Marius Pharmaceuticals

Shalin Shah

Co-CEO, Marius Pharmaceuticals

Follow this link:
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX...

Male Hormone Replacement Therapy And The Side Effects – Nerd’s Magazine

Testosterone replacement therapy is done to restore the testosterone levels in men. It is referred to ashormone replacementtherapy. Testosterone is a hormone in men that is produced in the testicles and helps to maintain sex drive, bone density, facial and body hair, sperm production, fat distribution, and red blood cells production. Testosterone levels are highest during adolescence and early stages of adulthood. The levels decline gradually as men age at around 30-40 years.

Testosterone in men may decline due to two reasons. First, it may be due to health conditions that have an effect on the testicles eg cancer, infection, and injury. The disease that results from low levels of testosterone is called hypogonadism. This condition prevents testosterone production by affecting the testicles and pituitary glands. Secondly, it may be as a result of natural decline as a man ages i.e. when men reach 30, they may start experiencing testosterone reduction. Low testosterone levels are considered normal but to some men, it may be extremely abnormal levels hence require replacement.

Decline testosterone levels can lead to symptoms such as reduced sexual desire with few erections that happen spontaneously, physical changes such as decreased muscle strength and mass, increased body fat, swollen and tender breasts, hair loss, fatigue, osteoporosis, emotional changes that lead to reduced motivation and self-esteem eg depression, and infertility. These symptoms can be a result of the side effects of the therapy, thyroid problems, diabetes, and obstructive sleep apnea. Hormone replacement therapy is administered to reverse the lowered testosterone levels in men. The therapy can be recommended to various people with the problem. Both healthy and aging men without hypogonadism diagnosis can be prescribed for testosterone replenishment on showing symptoms. Very high levels of testosterone on the other hand can also cause side effects such as the risk of stroke, infertility, enlarged breasts, and enlarged prostate.

There are several ways in which testosterone replacement can be administered. Testosterone can be taken in gels, intramuscular injections, patches, and topical creams. The method used for administration depends on ones lifestyle and the type of medical need. It can also be taken orally while being monitored to prevent it from being too high. Hormone replacement therapy is meant to induce and maintain secondary characteristics and to correct the symptoms and side effects arising due to low testosterone levels. Testosterone therapy can have some effects when used to prevent normal aging. It worsens sleep obstruction a disorder that causes abrupt stop and start of breathing, promotion of prostate cancer growth, stimulated overproduction of red blood cells increasing blood clotting risks, and reduction in sperm production or testicle shrinkage.

Hypogonadism can be diagnosed as primary or secondary hypogonadism. Abnormalities in testicular levels should be diagnosed, treated, and monitored. Hypogonadism causes testis failure hence reduced production of testosterone concentration and affect the normal number of spermatozoa. It can result from either defect that causes a change in the testis or the hypothalamus. Primary hypogonadism is a result of low T levels, raised gonadotropin levels, or impaired spermatogenesis. Causes of primary hypogonadism include trauma, HIV infection, cancer chemotherapy, myotonic dystrophy, testes exposure to radiation, and infectious orchitis. Secondary hypogonadism is due to low T levels, low or unsuitably normal gonadotropin levels, and spermatogenesis impairment. It is caused by severe obesity, androgenic anabolic steroid withdrawal, hypothalamic tumours, pituitary tumour, and surgery and deprivation therapy of androgen with gonadotropin.

Before testosterone therapy is administered, the clinicians discuss the potential risks and the need for monitoring. Urological evaluation is necessary for men with prostate nodule or induration. In older men, testosterone therapy has a life expectancy of up to 10 years and above. The therapy may lead to side effects and risks such as prostate cancer risk and require prostate monitoring. Some of the symptoms that are evident during T administration include.

Acne and oily skin

Reduced sperm production and fertility

Detection of subclinical cancer

Erythrocytosis

Metastatic prostate cancer growth

Male pattern balding

Breast cancer growth

Obstructive sleep apnea

Heart attack and heart disease

Before settling for testosterone therapy, it is important to take a few cations and think about all the aspects of the therapy. First, analyzing ones health history is key.it is advisable to first consider any other reasons that may be causing the symptoms that are similar to those of low testosterone levels. Sex dysfunctions can also be due to psychological or relationship issues. Cardiovascular disease can also be the reason behind erectile dysfunction. Several clinical measurements may be required to fully diagnose low testosterone levels. The tests are done on varied days and detailed interpretation is needed to establish the amounts of available testosterone. It is also necessary to have information on the possible risks and effects of the therapy and the side effects of the different methods used in administering testosterone.

Baseline evaluation before T administration is done helps to identify and exclude those prone to prostate cancer or who have a high risk of developing prostate cancer. Screening and monitoring in the case of cancer risk require patient and doctor agreement and patient awareness. Factors that should be considered during the baseline assessment are age, race, family history, and prostate examination results. Patient administered with T therapy requires frequent monitoring and assessment to establish whether the therapy is working and in case there are any adverse effects, and that they are responding to the treatment regimen. During the first 12 months of T treatment, it is advisable to get urological consultation to identify ant abnormalities.

Testosterone decline can be due to aging or medical conditions. The treatment and restoration of the levels of testosterone are referred to as testosterone replacement therapy. This therapy requires diagnosis, treatment, and constant monitoring. This is because the therapy treatment has different side effects and risks that vary from one patient to another. A qualified specialist team atLiv Naturalhelps by providing solutions to testosterone deficiency and solve any other health problems that result from low testosterone levels such as erectile dysfunction, low libido, and low muscle mass. Low T levels can only be determined by a diagnosis administered by clinicians i.e. testosterone level test.

(Visited 6 times, 6 visits today)

Go here to read the rest:
Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine

New York Medical and Life Sciences: Year in Review 2020 – JD Supra

From contraceptives to mesh implants, shampoos to pasta, New York state and federal courts issued decisions in 2020 which further shaped the landscape in the medical and life sciences legal world. To prepare the best product liability and class action defense strategies for pharmaceuticals, medical devices and other FDA regulated products, it is often helpful to step back and review holdings that have affected the industry and may shape the year ahead.

In the New York Medical and Life Sciences: Year in Review 2020, we review, analyze and share potential implications for future life science cases, based on several key judicial holdings in New York in 2020 pertaining to:

In Re: Mirena IUS Levonorgestrel-Related Products Liability Litigation (No. II), 982 F.3d 113 (2d Cir. 2020)

In an appeal from a judgment of the United States District Court for the Southern District of New York granting summary judgment in favor of Bayer dismissing mass tort plaintiffs' products liability Mirena claims after preclusion of the opinions of all of plaintiffs expert witnesses on general causation, the Second Circuit affirmed. Plaintiffs argued that the district court abused its discretion by (1) focusing on plaintiffs' experts' conclusions rather than their methodologies, (2) requiring the experts to back their opinions with published studies that definitively supported their conclusions, and (3) taking a "hard look" at the experts' methodology. The Second Circuit held that plaintiffs may challenge whether the district courts reliability analysis was correct, but plaintiffs had no basis to argue that the district court did not engage in a detailed analysis of their experts' methodologies. An expert need not back his/her opinion with published studies that support his/her conclusion if he/she has utilized reliable scientific methods to reach that conclusion. But here, because the district court found that plaintiffs' experts did not otherwise reliably utilize scientific methods and the conclusions were not supported by other studies, the experts' reports were properly excluded. Not only was it appropriate for the district court to take a hard look at plaintiffs' experts' reports, the court was required to do so to ensure reliability. Plaintiffs also argued that the district court erred in precluding differential-diagnosis evidence, which they argued would have shown general causation. While the Second Circuit declined to adopt a bright-line rule that "a differential diagnosis may never provide a sufficient basis for an opinion as to general causation," they explained that the district judge had broad discretion in determining whether in a given case a differential diagnosis is enough by itself to support such an opinion. And here it was not.

English v Bayer, 468 F. Supp.3d 573 (W.D.N.Y. 2020)

Plaintiffs, three former users of Essure, a Class III medical device contraceptive implant, subject to Pre-Market Approval procedures, and granted PMA by the FDA, asserted causes of action for negligent training of physicians, breach of express warranty and negligent misrepresentation (advertising concerning safety and effectiveness at preventing pregnancy, and qualifications of implanting physicians), negligent risk management (failing to report adverse events to the FDA), and negligent failure to warn. Defendants moved pre-Answer to dismiss under FRCP 12(b)(6) on the basis that plaintiffs claims were entirely preempted by the Medical Device Amendments to the federal Food Drug and Cosmetic Act. The court found plaintiffs did not plausibly allege that the FDA-approved training requirements placed any duty on defendants to do so. To the extent that plaintiffs claimed that defendants did deviate from FDA-approved training requirements by failing to ensure that implanting physicians completed preceptoring requirements, read and understood the Physician Training Manual, and successfully completed simulator training, those claims did not seek to impose obligations beyond those mandated by the FDA, and thus arguably were not expressly preempted. However, they were nonetheless impliedly preempted since plaintiffs did not plead any parallel state law cause of action that supported their negligent training claims, nor did their opposition identify any New York law establishing liability on the part of a non-employer for injuries to third parties arising out of alleged negligent training. With respect to plaintiffs failure to report adverse events to the FDA claims, even if they were characterized as a failure to warn, they were expressly preempted: plaintiffs could not maintain a claim that defendants were required to issue additional warnings beyond what the FDA prescribed and approved. Furthermore, as a standalone claim, failure to report adverse events to the FDA is not a cognizable cause of action under New York law.

Montero v. Teva Pharmaceuticals USA Inc. et al., No. 19 Civ. 9304, 2020 WL 1862593 (S.D.N.Y. April 14, 2020)

Plaintiff alleged that she developed blood-clots, resulting in a pulmonary embolism, as a result of using an oral contraceptive, marketed as a generic drug. The complaint asserted causes of action for negligence, strict liability, breach of warranty, fraud and negligent misrepresentation. On a FRCP 12(c) motion for judgment on the pleadings, the court dismissed the warning and design claims as preempted, citing Supreme Court precedents (PLIVA, Inc. v. Mensing 564 U.S. 604 (2011) and Mut. Pharm. Co. v. Bartlett, 570 U.S. 472 (2013)). Moreover, plaintiff could not proceed on her other claims, including a failure to test theory, a theory premised on the suggestion that such testing would have shown that the oral contraceptive was too dangerous for the market. That argument is inconsistent with Bartlett, which held that the stop-selling rationale that products should be pulled from the market is incompatible with preemption jurisprudence because preemption cases presume that an actor seeking to satisfy both his federal and state law obligations is not required to cease acting altogether in order to avoid liability.

Contraceptives Potential implication for future cases: In contraceptive product liability actions, whether the product is regulated as a drug or a device, preemption remains a first line of defense. Even non-traditional theories, such as failure to test, train or report AERs, are vulnerable to dismissal. New York continues to be wary of admitting differential diagnosis expert opinion on issues of general causation.

Balura v Ethicon, No. 3:19-CV-1372, 2020 WL 819293 (N.D.N.Y. Feb. 19, 2020)

In a massive products liability multi-district litigation involving transvaginal surgical mesh used primarily to treat pelvic organ prolapse and stress urinary incontinence, defendants moved to exclude a specific causation expert alleging differential diagnosis, as the opinion was replete with factual errors, which prohibited him from forming a proper foundation for his opinions. The court ruled that the differential diagnosis opinion was suitable in a specific causation analysis. However, the opinion that plaintiffs pelvic injuries were caused by a defective device without specifying any design defect was insufficient under New York law. The court ruled the expert failed to describe or explain how a defect in the mesh caused plaintiffs injuries, as opposed to the mere presence of the mesh itself. Finally, the experts opinions about alleged future complications were speculative and unreliable, as not consistent with Dauberts methodology requirements.

Arruda v. C.R. Bard, No. 6:19-cv-1523, 2020 WL 4569436 (N.D.N.Y. Aug. 6, 2020)

In a product liability matter involving Align, a 510K device, defendant contended that plaintiff could not prevail on a design defect claim unless she also demonstrated a failure to warn. Defendant argued that a medical device that is implanted and requires a prescription is a Comment K unavoidably unsafe product to which strict products liability would not normally apply. Defendant, however, largely relied on cases that involved prescription drugs, not devices. The court noted the Second Circuit would assess the viability of a design defect claim under the legal standard for such claims in New York a utility/risk analysisrather than by applying the unavoidably unsafe products exception. The court thus did not require plaintiff to show a failure to warn in order to maintain a design defect claim. Defendants attempt to have the court adopt a categorical approach to the exception stated in Comment K, finding that any medical device implanted pursuant to a prescription is unavoidably unsafe, was rejected. Among other things, the court denied defendants motion for summary judgment on design defect and failure to warn claims.

Dunham v. Covidien, 19-cv-2855, 2020 WL 5995102 (S.D.N.Y. Oct. 9, 2020) and Krulewich v Covidien, No. 19-cv-2857, 2020 WL 5995103 (S.D.N.Y. Oct. 9, 2020)

In a Covidien mesh action, defendant moved to dismiss claims for common law strict products liability (manufacturing defect, design defect, and failure to warn), negligence, breach of warranty (express and implied), negligent and fraudulent misrepresentation, unconscionable commercial practices under New York General Business Law Sections 349 and 350, unjust enrichment, and punitive damages, which was granted. Dunham v. Covidien. On the same day, the same court dismissed claims for common law strict products liability (manufacturing defect, design defect, and failure to warn), negligence, breach of warranty (express and implied), negligent and fraudulent misrepresentation, unconscionable commercial practices under New York General Business Law Sections 349 and 350, unjust enrichment, punitive damages, and loss of consortium. Krulewich v Covidien. In both cases, plaintiffs proposed alternative design was to use polypropylene instead of polyester. Plaintiffs did not adequately plead that the use of polyester was a substantial factor in causing the injuries. The plaintiffs thus failed to allege adequately a design defect claim. The court also found deficiencies in the plaintiffs failure to warn claims because the allegations did not identify how the warnings given were insufficient to warn physicians and the plaintiffs of the potential dangers of using the mesh. The warnings provided noted the risks of the complications that plaintiff actually experienced, namely, chronic pain, adhesion, and hernia recurrence.

Surgical MeshPotential implication for future cases: Surgical mesh plaintiffs must adequately plead their design defect and warning claims under traditional New York concepts of product liability. New York approaches design defect for a medical device under a risk utility balancing approach, not as an unavoidably unsafe product. Plaintiffs must specify the design defect through expert witness opinion evidence.

Gayle v. Pfizer, Inc., 452 F. Supp.3d 78 (S.D.N.Y. 2020).

24 plaintiffs claimed the cholesterol drug Lipitor caused their type II diabetes. Pfizer moved for judgment on the pleadings under FRCP 12(c) on the basis that if the claims arose after the 2012 Lipitor label change, they were preempted and if the claims arose before April 2016 they were time-barred. The court found the claims preempted, even though plaintiffs theorized 6,000 adverse event reports relating to diabetes from Pfizer to the FDA constituted newly acquired information which would enable the manufacturer to change the label under the FDAs Changes Being Effected (CBE) regulations. In order to qualify as "newly acquired information," the information must demonstrate "reasonable evidence of a causal association with a drug" 21 C.F.R. 201.57. But the fact that a user of a drug has suffered an adverse event, standing alone, does not mean that the drug caused that event. Additionally, while plaintiffs did not allege when their claims accrued, to the extent they accrued before April 2016, they were deemed untimely. Applying New Yorks borrowing statute CPLR 202 (which applies the shorter of the New York or other state statute of limitations) the court found the claims untimely. Plaintiffs could not take advantage of New Yorks discovery rule allowing plaintiffs to bring a claim one year after discovery of the cause of the injuries, because plaintiffs would still be caught in the preemption trap. Plaintiffs did not plead that technical, scientific or medical knowledge and information sufficient to ascertain the cause of their injury had not been discovered. Nor did plaintiffs plead with particularity that Pfizer fraudulently concealed the information, to equitably toll the statute of limitations.

Potential implication for future cases: Adverse event reports are not evidence of causation, and do not enable plaintiffs to do an end-run around preemption.

Vardouniotis v. Pfizer, 2020 NY Slip Op 32233(U) (Sup. Ct., NY County 2020)

In a state court action involving Chantix, a smoking cessation medication manufactured by Pfizer, defendant moved, pursuant to CPLR 3211(a)(7), to dismiss the verified complaint. The court dismissed the negligence, gross negligence, and willful, wanton and malicious conduct claims insofar as those causes of action were based upon failure to warn allegations, as well as the breach of express warranty, fraudulent misrepresentation, fraudulent concealment, reckless and/or negligent misrepresentation and concealment claims, and the plaintiffs request for punitive damages. Plaintiff argued that the label for Chantix did not include warnings for dystonia, muscular spasm, movement disorders and abnormal posture, which are typically due to neurological disease or a side effect of drug therapy. According to the plaintiff, Pfizer knew or should have known of these side effects, citing newspaper articles and scientific journal publications identifying adverse effects, especially those experienced by the plaintiff, not identified in the Chantix label. Although plaintiff cited newspaper articles and journal articles in her memorandum of law, these articles were not annexed to the complaint or her opposition to Pfizers motion to dismiss. The court declined to take Judicial Notice of facts alluded to, as that is reserved for matter[s] of common and general knowledge, well-established and authoritatively settled. Prince, Richardson on Evidence 2-201 (Farrell 11th ed). There was no showing that these websites were of sufficient authenticity and reliability. Plaintiff also alleged negligence, gross negligence and that Pfizer was wanton and malicious in its actions, misrepresentations, and omissions as a result of Pfizers failure to adequately test Chantix and failure to conduct post-marketing surveillance. Pfizers motion seeking dismissal of these claims was denied. Breach of express warranty was dismissed as no express warranties were pled or presented but the plaintiff adequately alleged that Pfizer breached the implied warranties of merchantability and fitness by holding Chantix out as reasonably fit and suitable when it was allegedly unreasonably dangerous. Unjust enrichment was not duplicative of any other claim, given that plaintiff sought disgorgement of Pfizers profits and monetary benefits. It is well-settled that conduct warranting an award of punitive damages need not be intentionally harmful but may consist of actions which constitute willful or wanton negligence or recklessness. Home Ins. Co. v American Home Prods. Corp., 75 NY2d 196, 204 (1990). Here, the complaint failed to allege that Pfizer engaged in any morally culpable conduct and plaintiffs request for punitive damages was denied.

Potential implication for future cases: New York State courts require that plaintiffs plead their complaints with particularity or be subject to early dismissal of claims not supported. AERs are not facts of which courts will take as Judicial Notice.

Crespo v Merck, No. 13-cv-2388, 2020 WL 5369045 (E.D.N.Y. Sep. 8, 2020), reconsideration denied 2020 U.S. Dist. LEXIS 188955 (E.D.N.Y., Oct. 12, 2020), appeal filed (Jan. 7, 2021)

Plaintiffs pro se brought this products liability action in the District of New Jersey. The Judicial Panel on Multidistrict Litigation transferred it to New York for coordinated pretrial proceedings, pursuant to 28 U.S.C. 1407. Plaintiff alleged sexual dysfunction from use of Propecia, was diagnosed with erectile dysfunction in 2003, and was diagnosed with hypogonadism in Florida, in 2009. At some point in 2009, his doctors discussed the possibility that plaintiffs use of Propecia had caused his sexual dysfunction. Merck moved for summary judgment on the basis of time bar, as plaintiffs filed the action on April 2, 2013. Generally, [a] federal court sitting in diversity jurisdiction applies the choice of law rules of the forum state. Forest Park Pictures v. Universal Television Network, Inc., 683 F.3d 424, 433 (2d Cir. 2012). When the JPML transfers a case, however, the transferee court applies the substantive state law, including choice-of-law rules, of the jurisdiction in which the action was filed. Menowitz v. Brown, 991 F.2d 36, 40 (2d Cir. 1993). The court applied New Jerseys choice-of-law rules, not the rules in New York. Here, two states had a potential interest in this action. New Jersey was the state in which plaintiffs filed the action, and the state in which defendants were incorporated, had their principal place of business, and made decisions regarding the labeling and marketing of Propecia. Florida was the state in which plaintiff was prescribed, purchased, and took Propecia. Plaintiff choose to file suit in New Jersey and there were no exceptional circumstance to justify departing from the general rule that New Jerseys statute of limitations applied, which barred plaintiffs claims.

Potential implication for future cases: In MDL cases, choice of law is not necessarily the law of the forum state, or the plaintiffs residence. Plaintiffs choice of forum may dictate choice of law.

Webb v Mentor, 453 F. Supp.3d 550 (N.D.N.Y. 2020)

MemoryGel silicone breast implants are Class III medical devices, approved by the FDA through the PMA process in 2006. Plaintiff sued in product liability (negligence based on failure to warn and manufacturing defect, negligence per se, strict liability in design and manufacturing defect, breach of express and implied warranty) and asserted claims related to the implants safety and effectiveness. Defendants moved to dismiss the complaint, asserting that plaintiffs claims were preempted, pursuant to the Medical Device Amendments of 1976, 21 USC 360c and, alternatively, that plaintiff failed to state any claims upon which relief may be granted, under FRCP 12(b)(6). To succeed in asserting a claim that fits through the narrow gap between express and implied preemption, plaintiff must identify a parallel law upon which she has based her state law claims. Plaintiff alleged that defendants did not comply with the FDAs Quality System Regulations and Current Good Manufacturing Practices (CGMPs). However, plaintiff failed to identify specific regulations or explain how defendants violated the CGMPs. Plaintiffs general allegations could not withstand preemption because she failed to establish the necessary link between defendants federal violations and her alleged causes of action. Plaintiffs failure to warn and design defect claims were preempted because she sought to impose safety related requirements on the device or labeling beyond those imposed by the FDA. Plaintiffs express and implied warranty claims were preempted; plaintiff did not identify specific representations of the manufacture which exceeded the scope of FDA approved labeling statements nor did she show defendants alleged federal violations caused the implants to have a deviated from their purpose, that they failed, or that they were unfit for patients.

Potential implication for future cases: PMA medical devices, including breast implants, continue to enjoy preemption in New York.

Berni v Barilla, 964 F.3d 141 (2d Cir. 2020)

Plaintiffs brought a class action against Barilla for deceptive packaging, alleging that Barilla intentionally sold its pasta in misleading boxes which concealed non-functional slack-fill, asserting claims under New York General Business Law section 349. The Second Circuit held future harm to pasta purchasers is not likely, and as a result, the injunctive relief sought would not provide a remedy for all members of the class. Pasta purchasers who alleged they were deceived were alleging past harm. Such past harm is of the kind that is commonly redressable at law through the award of damages, not injunctive relief. The district court did, in fact, err in certifying a Rule 23(b)(2) class because not all class members stand to benefit from injunctive relief, the kind of relief the settlement primarily provides. The Second Circuit held that past purchasers of a productlike the purchasers of Barilla pasta in this casewere not eligible for class certification under FRCP Rule 23(b)(2).

Sibrian v Cento Fine Foods, Inc., No. 19-CV-0974, 2020 WL 3618953 (E.D.N.Y. July 2, 2020)

Plaintiffs alleged misleading labeling of canned tomato products from Italy labeled Certified San Marzano under New York General Business Law sections 349 and 350. The court dismissed these claims as conclusory and strained, as the reasonable consumer would not have an expectation that a San Marzano tomato must be certified by the Consortium of the San Marzano Tomato Protected Designation of Origin. Plaintiffs did not allege that Cento falsely claimed the product was certified by the Consortium, and Consortium-certified seals did not appear on the product labels. Rather, plaintiffs contended the labeling and packaging created the impression of that certification. While there might be a few consumers who expect a San Marzano tomato to be certified by the Consortium, drawing upon common sense and common experience, the vast majority of reasonable consumers expect no such thing.

Steele v Wegmans, No. 19 Civ. 9227, 2020 WL 3975461 (S.D.N.Y. July 14, 2020)

Plaintiffs claimed deceptive acts or practices in violation of federal, New York, and Pennsylvania statutes and standards, false advertising, common-law negligent misrepresentation, fraud, breach of warranty and unjust enrichment alleging they were deceived into believing Wegmans ice cream was flavored with vanilla beans or extract. Upon a motion to dismiss, the court found the label on the ice cream container did not misrepresent the container's contents and the plaintiffs elaborate gas chromatography-mass spectrometry analysis chemists performed failed to show there was fraudulently little vanilla bean extract in the ice cream. Similarly in a case involving vanilla almond milk the SDNY found the term vanilla by itself does not communicate to a reasonable consumer that the product was made exclusively with vanilla bean and a reasonable consumer would understand vanilla refers to a flavor, not an ingredient. Cosgrove et al. v. Blue Diamond Growers, No. 19-Civ-8993 (S.D.N.Y. December 7, 2020).

Price v LOral, No. 17 Civ. 614, 2020 WL 4937464 (S.D.N.Y. Aug. 24, 2020)

After certification of two classes of New York and California consumer fraud plaintiffs who claimed they were deceived into purchasing Matrix Biolage Advanced line of Keratin shampoos and conditioners because they contained Keratin, defendants LOral and Matrix moved to exclude plaintiffs experts and both sides moved for summary judgment. The motion to exclude plaintiffs marketing expert opinion on consumer perceptions was granted in part and the economic expert opinion on class-wide damages was excluded as unreliable. Except for the breach of contract claim dismissed under New York law, the summary judgment motions were denied.

Devane v. LOral, No. 19 Civ. 4362, 2020 WL 5518484 (S.D.N.Y. Sept. 16, 2020)

Purported class action plaintiffs alleged LOral deceptively marketed and labeled Eversleek Keratin Caring products to make consumers believe the shampoos and conditioners contained Keratin, even though the products were labeled as vegan and Keratin was not on the ingredient list. Upon a motion to dismiss fraud, warranty and consumer fraud statutory claims (Alabama, Florida and New York), the court analyzed the claims under the reasonable consumer standard. The Second Circuit has noted it is not reasonable to assume that a product contains an ingredient when it is not on the ingredient list. As the product label was clear that the shampoos and conditioners cared for Keratin already found in hair and Keratin was not a listed ingredient, the court dismissed the entire case as not plausible.

Class ActionsPotential implication for future cases: Federal courts in New York scrutinize purported class actions involving FDA-regulated products for plausibility and expert support. The reasonable consumer, drawing on common sense and common experience, does not assume a product contains an ingredient not listed on the label.

The developments of 2020 indicate that it is critical to remain informed about changes in the law in order to develop the strongest product liability defense of pharmaceuticals and medical devices. We know it takes an enormous investment to develop innovative pharmaceuticals and medical devices to improve life experiences. Thats why our attorneys, with a national reputation for aggressively defending some of the largest entities in the regulated pharmaceutical, medical device, cosmetics and nutritional supplement industries, leverage their combination of medical and legal credentials to protect your critical life sciences products.

View post:
New York Medical and Life Sciences: Year in Review 2020 - JD Supra

Male menopause: symptoms, diagnosis and treatment – Netdoctor

We've all heard of the menopause, when a woman's reproductive function starts to slow down but do men experience something similar? The term 'male menopause' refers to the physical and emotional changes that some men experience as they get older. It's a surprisingly controversial topic and experts are divided on the subject, with many disagreeing on what it is, how is should be defined, and if it even exists.

But while debate rages on about what to call this life stage, if you're a man in your late forties or older and you experience worrying symptoms including erectile dysfunction, a loss of sex drive, depression, or fatigue, it is worth getting checked out.

We spoke to nutritionist and male hormone expert Roberta Stringer, co-founder of testosterone health brand DNA, and Dr Luke Pratsides, lead GP at Numan, about the male menopause symptoms, causes and treatment options:

The male menopause, also known as andropause or colloquially as 'manopause' is a term used to describe a cluster of symptoms associated with an age-related decline in testosterone. Despite the name, male menopause differs substantially from female menopause.

Unlike the hormonal drop that occurs in women during this time, sex hormones tend to decrease more gradually in men. Not every man will experience andropause whereas all women experience menopause and men can still reproduce, while women can no longer become pregnant naturally.

'Male menopause is the gradual reduction of testosterone specifically related to ageing,' says Dr Pratsides. 'It is not strictly a menopause, which specifically refers to the cessation of menstruation in women where ovulation ends and hormone production plummets during a relatively short period of time instead, it happens over many years.'

Unlike the hormonal drop that occurs in women during this time, sex hormones tend to decrease more gradually in men.

Male menopause is not recognised as a medical condition. The term is often used alongside testosterone deficiency syndrome (TDS), which occurs when the testes produce few or no hormones. TDS is characterised by abnormally low testosterone levels (below 300 ng/dL) and has many different causes.

While it's true that many older men experience TDS approximately 40 per cent of men over the age of 45, according to a study published in the journal Frontiers in Endocrinology, and 50 per cent over the age of 80 abnormally low testosterone levels are not an inevitable result of ageing.

'Some men still maintain a normal level of testosterone throughout their lives, experience no symptoms and can father children well into their eighties,' says Dr Pratsides. TDS can affect men of any age, but when it occurs later in life, it's known as late-onset hypogonadism or androgen decline in the ageing male (ADAM).

The symptoms associated with male menopause are attributed to a gradual age-related decease in testosterone levels. 'Testosterone peaks at around the age of 20 in men,' says Stringer. 'Depending on health, diet and lifestyle factors, testosterone levels should remain consistent during men's twenties. They decline steadily from 30 at around one per cent a year.'

While declining T-levels are a given, 'the extent of decline and the age at which this happens varies even more so with today's lifestyle factors,' she says. The effects appear to be accelerating. One US study identified a 'substantial' drop in the general population since the 1980s, with testosterone levels declining by one per cent per year on average.

Stress, smoking, poor sleep, high body mass index, certain medications, lack of exercise and alcohol are all known to sap testosterone levels. Low T has also been linked to conditions like type 2 diabetes, high cholesterol, high blood pressure, metabolic syndrome and obesity, though it's unclear whether it's a cause or effect.

So, why is male menopause controversial? Some experts suggest that a gradual age-related drop in testosterone is not the primary cause of male menopause symptoms. They believe lifestyle and psychological factors play a far more prominent role. For example, feeling stressed because of problems at work could affect your libido and energy levels.

Male menopause is associated with physical, sexual, and psychological symptoms, that tend to emerge slowly and worsen as you grow older. 'Some men notice symptoms from their thirties, others in their sixties, and some particularly the older generation who were brought up at a time where male hormonal health was not discussed may not acknowledge any change at all,' says Stringer.

Common male menopause symptoms include:

If you're experiencing any of the symptoms associated with male menopause or have any concerns, make an appointment with your doctor.

When you visit your GP they will carry out a detailed check-up based on each of your specific symptoms and address them accordingly. They will also make sure to exclude other medical issues with relevant scans or tests as required.

Your doctor will carry out a detailed check-up based on each of your specific symptoms and address them accordingly.

Your doctor might ask about your personal life to determine whether other factors, such as stress or anxiety, play a part. They may also take a sample of your blood to test your testosterone levels. This will likely take place early or mid-morning, since your testosterone levels fluctuate though the day. A level of less than seven indicates low testosterone. Between seven and 14 is borderline, so further tests may be needed.

Some male menopause symptoms can be treated with hormone replacement therapy if your testosterone levels are found to be low. 'Testosterone replacement can be given in gels, patches, or injections,' says Dr Pratsides. 'It should always be guided by a suitably qualified clinician and obtained from a regulated provider.'

Testosterone treatment has various risks and side effects, including acne, worsened prostate cancer, enlarged breasts, disturbed breathing while sleeping (sleep apnea) and high red blood cell counts, which increases your risk of forming a blood clot. Men using testosterone therapy long-term appear to have a higher risk of heart disease.

If your symptoms are attributed to a combination of physical, lifestyle, and psychological factors, your doctor may adopt a more holistic approach. 'Symptoms of low testosterone due to advancing age can be treated individually,' says Dr Pratsides, 'for example, Viagra to help treat erectile dysfunction, or counselling to treat low mood.'

The simplest way to manage symptoms of male menopause is by making healthier lifestyle choices. Eating a well-balanced diet, making time for regular exercise, getting enough enough sleep, reducing your stress levels, and minimising alcohol and tobacco use are all recommended.

Hormone therapy isn't the only way to give your testosterone reserves a boost. Here are four evidence-based ways to increase your testosterone levels naturally:

Optimise your diet with a balance of carbs, healthy fats and protein. And don't forget the micronutrients. 'Nutrient deficiencies are increasingly common and can cause significant issues for maintaining positive testosterone levels,' says Stringer. B vitamins and zinc are particularly potent, improving sperm quality by 74 per cent in one study. 'Increasing your magnesium intake can raise testosterone levels within a month,' she adds.

Keep your favourite tipple for special occasions. 'Alcohol directly inhibits the production of testosterone in your testes,' says Stringer. 'It can also impact sleep as testosterone levels replenish overnight, this in turn can further impact levels.' Getting five hours a night can slash your T-levels by as much as 15 per cent, the University of Chicago Medical Centre found.

Maintain a healthy weight and pay attention to body fat levels, says Stringer. 'Obesity has a direct and negative impact on testosterone levels,' she explains. 'Fat cells metabolise testosterone to oestrogen, lowering testosterone levels. Also, obesity reduces levels of sex hormone binding globulin (SHBG), a protein that carries testosterone in the blood. Less SHBG means less testosterone.'

If you don't have a workout routine, now's the time to start. 'A 2004 study of older men found that regular physical activity increased testosterone and growth hormone (GH) levels as well as have a positive effect on brain function,' says Stringer. 'Resistance training has shown to be particularly beneficial for testosterone levels.'

Last updated: 28-01-2020

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

See the article here:
Male menopause: symptoms, diagnosis and treatment - Netdoctor

Freeman: ‘Pressure to Succeed’ Led to Testosterone Order – Medscape

MANCHESTERThe "pressure" to succeed and willingness to take risks and put what some riders wantedbefore anti-doping rules caused ex-British Cycling and Team Sky head doctor Richard Freeman to order banned testosterone, a medical tribunal heard.

Dr Freeman is accused of ordering 30 sachets of Testogel to the national velodrome in May 2011 in order to dope a rider.

He admits placing the order but claims he was "bullied" into it by head cycling coach Shane Sutton to help treat his erectile dysfunction.

Mr Sutton has denied this and claims Dr Freeman is lying.

In closing submissions before a Medical Practitioners Tribunal Service (MPTS) fitness to practice hearing in Manchester, Simon Jackson QC, for the GMC, discussed a report by endocrinologist Dr Richard Quinton.

Dr Quinton had previously told the tribunal there was no evidence the Testogel was clinically indicated for Shane Sutton.

Mr Jackson said that Dr Freeman "must have known" that was the case and had later "abandoned" that suggestion and instead claimed he'd been bullied.

He said there was no evidence the Testogel was a "step-wise" increase in treatment because there were no records of Viagra (Sildenafil) or Cialis (Tadalafil) being prescribed to Mr Sutton before 2011.

But Cialis was prescribed in 2014 and 2015 which indicated, in Dr Quinton's opinion, that it was working.

Mr Jackson said Dr Quinton had accepted Testogel did have evidence-based off-label uses but he did not accept a single one-off prescription of 30 sachets was indicated in this case.

It had also been prescribed without Dr Freeman undertaking any examination, he said.

Dr Quinton had told the hearing, Mr Jackson said, the Testogel would have "no effect" unless a patient had hypogonadism and Mr Sutton didn't have that condition.

"In his words," Mr Jackson continued, "only 'dodgy doctors still prescribe testosterone in these inappropriate circumstances, namely for a placebo effect.'"

He pointed out that Dr Freeman had admitted in evidence that he'd hadn't prescribed the Testogel as a placebo.

Dr Freeman told UKAD (UK Anti-Doping) investigators in an interview in February 2017 that the Testogel was intended for a non-athlete.

But Mr Jackson questioned why a letter drafted by the doctor's solicitor to UKAD, which asked Mr Sutton to waive his patient confidentiality so those claims could be backed up, had not mentioned any condition or the Testogel.

Mr Jackson told the tribunal that Dr Freeman had repeatedly told lies and they were "part of an established pattern of dishonesty as part of a cover-up".

The lies provided "misleading and ultimately dishonest answers" for why the Testogel had been ordered, he said, and Dr Freeman had been prepared "to keep going and involve other people in this web of deceit".

In summary, Mr Jackson said the GMC's case was that Dr Freeman had placed the order when it wasn't clinically indicated and the intended use was to boost a rider's performance.

He also claimed there was no evidence Mr Sutton had bullied him into it.

"Not only was there no bullying related to the ordering," he said, "there is no basis for concluding that Mr Sutton wanted it, needed it or would have benefited from it in order for him to bully to obtain it.

"But rather we look at all the other circumstances of the pressure on Dr Freeman to succeed, the demonstration that he was a risk-taker and continued to take risks."

Mr Jackson added that Dr Freeman, by his own admission, looked at "what the riders wanted and he didn't focus on what the code prevented".

Dr Freeman has admitted 18 of 22 charges against him, which include lying after attempting to cover-up the order and lying to UKAD.

He's also admitted charges relating to prescribing medicine to non-athlete members of staff and failing to maintain adequate records.

The four charges he denies all relate to the central charge of "knowing or believing" the order was intended to improve an unknown rider's performance.

Mary O'Rourke, Dr Freeman's QC, will begin her final submissions today (Tuesday).

See the rest here:
Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape

Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ – NeighborWebSJ

Hormone replacement therapy refers to the treatment of the patients with hormone deficiency due to conditions such as dwarfism or women nearing menopause, which requires replacement of hormones in the body whose levels have become low. Market competition is intense. Eli Lilly, Pfizer, AbbVie, Novo Nordisk, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 players combined 45.13% market share in all.

Market Analysis and Insights:

Global Hormone Replacement Therapy Market The global Hormone Replacement Therapy market size is projected to reach US$ 17720 million by 2026, from US$ 16210 million in 2019, at a CAGR of 1.5% during 2021-2026.

Get Sample Copy of This Report @

https://www.qyresearch.com/sample-form/form/2626362/global-hormone-replacement-therapy-market

:

Global Hormone Replacement Therapy Scope and Segment Hormone Replacement Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Replacement Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2016-2027. The following manufacturers are covered in this report:, Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva, Novartis, Abbott, Roche, Endo International, Ipsen, ANI Pharmaceuticals, TherapeuticsMD

Hormone Replacement Therapy Breakdown Data by Type

Estrogen Hormone, Growth Hormone, Thyroid Hormone, Testosterone Hormone, The proportion of estrogen hormone in 2018 is about 50%, and the proportion is in increasing trend from 2014 to 2018.

Hormone Replacement Therapy Breakdown Data by Application

Menopause, Hypothyroidism, Growth Hormone Deficiency, Male Hypogonadism, Other Diseases, The most proportion of hormone replacement therapy is used in menopause, and the proportion in 2018 is 46.2%. Regional and Country-level Analysis The Hormone Replacement Therapy market is analysed and market size information is provided by regions (countries). The key regions covered in the Hormone Replacement Therapy market report are North America, Europe, China, Japan and Middle East. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. The report includes country-wise and region-wise market size for the period 2016-2027. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2016-2027. Competitive Landscape and Hormone Replacement Therapy Market Share Analysis

Get Full Report In Your Inbox Within 24 Hours at USD(4900):

https://www.https://www.qyresearch.com/settlement/pre/d0bdf868b40c675b096a10b57783b083,0,1,global-hormone-replacement-therapy-market

Table of Contents

1 Study Coverage 1.1 Hormone Replacement Therapy Product Introduction 1.2 Market by Type1.2.1 Global Hormone Replacement Therapy Market Size Growth Rate by Type1.4.2 Estrogen Hormone1.4.3 Growth Hormone1.2.4 Thyroid Hormone1.2.5 Testosterone Hormone 1.3 Market by Application1.3.1 Global Hormone Replacement Therapy Market Size Growth Rate by Application1.3.2 Menopause1.3.3 Hypothyroidism1.3.4 Growth Hormone Deficiency1.3.5 Male Hypogonadism1.3.6 Other Diseases 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Hormone Replacement Therapy Sales Estimates and Forecasts 2016-2027 2.2 Global Hormone Replacement Therapy Revenue Estimates and Forecasts 2016-2027 2.3 Global Hormone Replacement Therapy Revenue by Region: 2016 VS 2021 VS 2027 2.4 Global Top Hormone Replacement Therapy Regions by Sales2.4.1 Global Top Hormone Replacement Therapy Regions by Sales (2016-2021)2.4.2 Global Top Hormone Replacement Therapy Regions by Sales (2022-2027) 2.5 Global Top Hormone Replacement Therapy Regions by Revenue2.5.1 Global Top Hormone Replacement Therapy Regions by Revenue (2016-2021)2.5.2 Global Top Hormone Replacement Therapy Regions by Revenue (2022-2027) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa 3 Competition by Manufacturers 3.1 Global Hormone Replacement Therapy Sales by Manufacturers3.1.1 Global Top Hormone Replacement Therapy Manufacturers by Sales (2016-2021)3.1.2 Global Top Hormone Replacement Therapy Manufacturers Market Share by Sales (2016-2021)3.1.3 Global Top 10 and Top 5 Companies by Hormone Replacement Therapy Sales in 2020 3.2 Global Hormone Replacement Therapy Revenue by Manufacturers3.2.1 Global Top Hormone Replacement Therapy Manufacturers by Revenue (2016-2021)3.2.2 Global Top Hormone Replacement Therapy Manufacturers Market Share by Revenue (2016-2021)3.2.3 Global Top 10 and Top 5 Companies by Hormone Replacement Therapy Revenue in 2020 3.3 Global Hormone Replacement Therapy Sales Price by Manufacturers 3.4 Analysis of Competitive Landscape3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)3.4.2 Global Hormone Replacement Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)3.4.3 Global Hormone Replacement Therapy Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type 4.1 Global Hormone Replacement Therapy Sales by Type4.1.1 Global Hormone Replacement Therapy Historical Sales by Type (2016-2021)4.1.2 Global Hormone Replacement Therapy Forecasted Sales by Type (2022-2027)4.1.3 Global Hormone Replacement Therapy Sales Market Share by Type (2016-2027) 4.2 Global Hormone Replacement Therapy Revenue by Type4.2.1 Global Hormone Replacement Therapy Historical Revenue by Type (2016-2021)4.2.2 Global Hormone Replacement Therapy Forecasted Revenue by Type (2022-2027)4.2.3 Global Hormone Replacement Therapy Revenue Market Share by Type (2016-2027) 4.3 Global Hormone Replacement Therapy Price by Type4.3.1 Global Hormone Replacement Therapy Price by Type (2016-2021)4.3.2 Global Hormone Replacement Therapy Price Forecast by Type (2022-2027) 5 Market Size by Application 5.1 Global Hormone Replacement Therapy Sales by Application5.1.1 Global Hormone Replacement Therapy Historical Sales by Application (2016-2021)5.1.2 Global Hormone Replacement Therapy Forecasted Sales by Application (2022-2027)5.1.3 Global Hormone Replacement Therapy Sales Market Share by Application (2016-2027) 5.2 Global Hormone Replacement Therapy Revenue by Application5.2.1 Global Hormone Replacement Therapy Historical Revenue by Application (2016-2021)5.2.2 Global Hormone Replacement Therapy Forecasted Revenue by Application (2022-2027)5.2.3 Global Hormone Replacement Therapy Revenue Market Share by Application (2016-2027) 5.3 Global Hormone Replacement Therapy Price by Application5.3.1 Global Hormone Replacement Therapy Price by Application (2016-2021)5.3.2 Global Hormone Replacement Therapy Price Forecast by Application (2022-2027) 6 North America 6.1 North America Hormone Replacement Therapy Market Size by Type6.1.1 North America Hormone Replacement Therapy Sales by Type (2016-2027)6.1.2 North America Hormone Replacement Therapy Revenue by Type (2016-2027) 6.2 North America Hormone Replacement Therapy Market Size by Application6.2.1 North America Hormone Replacement Therapy Sales by Application (2016-2027)6.2.2 North America Hormone Replacement Therapy Revenue by Application (2016-2027) 6.3 North America Hormone Replacement Therapy Market Size by Country6.3.1 North America Hormone Replacement Therapy Sales by Country (2016-2027)6.3.2 North America Hormone Replacement Therapy Revenue by Country (2016-2027)6.3.3 U.S.6.3.4 Canada 7 Europe 7.1 Europe Hormone Replacement Therapy Market Size by Type7.1.1 Europe Hormone Replacement Therapy Sales by Type (2017-2027)7.1.2 Europe Hormone Replacement Therapy Revenue by Type (2017-2027) 7.2 Europe Hormone Replacement Therapy Market Size by Application7.2.1 Europe Hormone Replacement Therapy Sales by Application (2017-2027)7.2.2 Europe Hormone Replacement Therapy Revenue by Application (2017-2027) 7.3 Europe Hormone Replacement Therapy Market Size by Country7.3.1 Europe Hormone Replacement Therapy Sales by Country (2017-2027)7.3.2 Europe Hormone Replacement Therapy Revenue by Country (2017-2027)7.3.3 Germany7.3.4 France7.3.5 U.K.7.3.6 Italy7.3.7 Russia 8 Asia Pacific 8.1 Asia Pacific Hormone Replacement Therapy Market Size by Type8.1.1 Asia Pacific Hormone Replacement Therapy Sales by Type (2018-2027)8.1.2 Asia Pacific Hormone Replacement Therapy Revenue by Type (2018-2027) 8.2 Asia Pacific Hormone Replacement Therapy Market Size by Application8.2.1 Asia Pacific Hormone Replacement Therapy Sales by Application (2018-2027)8.2.2 Asia Pacific Hormone Replacement Therapy Revenue by Application (2018-2027) 8.3 Asia Pacific Hormone Replacement Therapy Market Size by Region8.3.1 Asia Pacific Hormone Replacement Therapy Sales by Region (2018-2027)8.3.2 Asia Pacific Hormone Replacement Therapy Revenue by Region (2018-2027)8.3.3 China8.3.4 Japan8.3.5 South Korea8.3.6 India8.3.7 Australia8.3.8 Taiwan8.3.9 Indonesia8.3.10 Thailand8.3.11 Malaysia8.3.12 Philippines 9 Latin America 9.1 Latin America Hormone Replacement Therapy Market Size by Type9.1.1 Latin America Hormone Replacement Therapy Sales by Type (2019-2027)9.1.2 Latin America Hormone Replacement Therapy Revenue by Type (2019-2027) 9.2 Latin America Hormone Replacement Therapy Market Size by Application9.2.1 Latin America Hormone Replacement Therapy Sales by Application (2019-2027)9.2.2 Latin America Hormone Replacement Therapy Revenue by Application (2019-2027) 9.3 Latin America Hormone Replacement Therapy Market Size by Country9.3.1 Latin America Hormone Replacement Therapy Sales by Country (2019-2027)9.3.2 Latin America Hormone Replacement Therapy Revenue by Country (2019-2027)9.3.3 Mexico9.3.4 Brazil9.3.5 Argentina 6 Middle East and Africa 6.1 Middle East and Africa Hormone Replacement Therapy Market Size by Type6.1.1 Middle East and Africa Hormone Replacement Therapy Sales by Type (2016-2027)6.1.2 Middle East and Africa Hormone Replacement Therapy Revenue by Type (2016-2027) 6.2 Middle East and Africa Hormone Replacement Therapy Market Size by Application6.2.1 Middle East and Africa Hormone Replacement Therapy Sales by Application (2016-2027)6.2.2 Middle East and Africa Hormone Replacement Therapy Revenue by Application (2016-2027) 6.3 Middle East and Africa Hormone Replacement Therapy Market Size by Country6.3.1 Middle East and Africa Hormone Replacement Therapy Sales by Country (2016-2027)6.3.2 Middle East and Africa Hormone Replacement Therapy Revenue by Country (2016-2027)6.3.3 Turkey6.3.4 Saudi Arabia6.3.5 U.A.E 11 Company Profiles 11.1 Eli Lilly11.1.1 Eli Lilly Corporation Information11.1.2 Eli Lilly Overview11.1.3 Eli Lilly Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.1.4 Eli Lilly Hormone Replacement Therapy Product Description11.1.5 Eli Lilly Related Developments 11.2 Pfizer11.2.1 Pfizer Corporation Information11.2.2 Pfizer Overview11.2.3 Pfizer Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.2.4 Pfizer Hormone Replacement Therapy Product Description11.2.5 Pfizer Related Developments 11.3 AbbVie11.3.1 AbbVie Corporation Information11.3.2 AbbVie Overview11.3.3 AbbVie Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.3.4 AbbVie Hormone Replacement Therapy Product Description11.3.5 AbbVie Related Developments 11.4 Novo Nordisk11.4.1 Novo Nordisk Corporation Information11.4.2 Novo Nordisk Overview11.4.3 Novo Nordisk Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.4.4 Novo Nordisk Hormone Replacement Therapy Product Description11.4.5 Novo Nordisk Related Developments 11.5 Merck KGaA11.5.1 Merck KGaA Corporation Information11.5.2 Merck KGaA Overview11.5.3 Merck KGaA Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.5.4 Merck KGaA Hormone Replacement Therapy Product Description11.5.5 Merck KGaA Related Developments 11.6 Mylan11.6.1 Mylan Corporation Information11.6.2 Mylan Overview11.6.3 Mylan Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.6.4 Mylan Hormone Replacement Therapy Product Description11.6.5 Mylan Related Developments 11.7 Bayer11.7.1 Bayer Corporation Information11.7.2 Bayer Overview11.7.3 Bayer Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.7.4 Bayer Hormone Replacement Therapy Product Description11.7.5 Bayer Related Developments 11.8 Teva11.8.1 Teva Corporation Information11.8.2 Teva Overview11.8.3 Teva Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.8.4 Teva Hormone Replacement Therapy Product Description11.8.5 Teva Related Developments 11.9 Novartis11.9.1 Novartis Corporation Information11.9.2 Novartis Overview11.9.3 Novartis Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.9.4 Novartis Hormone Replacement Therapy Product Description11.9.5 Novartis Related Developments 11.10 Abbott11.10.1 Abbott Corporation Information11.10.2 Abbott Overview11.10.3 Abbott Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.10.4 Abbott Hormone Replacement Therapy Product Description11.10.5 Abbott Related Developments 11.1 Eli Lilly11.1.1 Eli Lilly Corporation Information11.1.2 Eli Lilly Overview11.1.3 Eli Lilly Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.1.4 Eli Lilly Hormone Replacement Therapy Product Description11.1.5 Eli Lilly Related Developments 11.12 Endo International11.12.1 Endo International Corporation Information11.12.2 Endo International Overview11.12.3 Endo International Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.12.4 Endo International Product Description11.12.5 Endo International Related Developments 11.13 Ipsen11.13.1 Ipsen Corporation Information11.13.2 Ipsen Overview11.13.3 Ipsen Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.13.4 Ipsen Product Description11.13.5 Ipsen Related Developments 11.14 ANI Pharmaceuticals11.14.1 ANI Pharmaceuticals Corporation Information11.14.2 ANI Pharmaceuticals Overview11.14.3 ANI Pharmaceuticals Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.14.4 ANI Pharmaceuticals Product Description11.14.5 ANI Pharmaceuticals Related Developments 11.15 TherapeuticsMD11.15.1 TherapeuticsMD Corporation Information11.15.2 TherapeuticsMD Overview11.15.3 TherapeuticsMD Hormone Replacement Therapy Sales, Price, Revenue and Gross Margin (2016-2021)11.15.4 TherapeuticsMD Product Description11.15.5 TherapeuticsMD Related Developments 12 Value Chain and Sales Channels Analysis 12.1 Hormone Replacement Therapy Value Chain Analysis 12.2 Hormone Replacement Therapy Key Raw Materials12.2.1 Key Raw Materials12.2.2 Raw Materials Key Suppliers 12.3 Hormone Replacement Therapy Production Mode & Process 12.4 Hormone Replacement Therapy Sales and Marketing12.4.1 Hormone Replacement Therapy Sales Channels12.4.2 Hormone Replacement Therapy Distributors 12.5 Hormone Replacement Therapy Customers 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 Hormone Replacement Therapy Industry Trends 13.2 Hormone Replacement Therapy Market Drivers 13.3 Hormone Replacement Therapy Market Challenges 13.4 Hormone Replacement Therapy Market Restraints 14 Key Findings in The Global Hormone Replacement Therapy Study 15 Appendix 15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer

About Us

QY Research is a leading global market research and consulting company. Established in 2007 QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship and our strong commitment to sustainability. Today, we are serving more than 4000 clients across five continents. Lets allow us to work closely with you and build a bold and a better future.

https://neighborwebsj.com/

Originally posted here:
Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ

Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,…

LOS ANGELES, United States: QY Research has recently published a research report titled, Global Male Hypogonadism Therapy Market Size, Status and Forecast 2021-2027. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Male Hypogonadism Therapy market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Male Hypogonadism Therapy market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Male Hypogonadism Therapy market.

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Male Hypogonadism Therapy market.

Key questions answered in the report:

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Male Hypogonadism Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 20271.2.2 Parenteral1.2.3 Transdermal1.2.4 Oral1.2.5 Others1.3 Market by Application1.3.1 Global Male Hypogonadism Therapy Market Share by Application: 2016 VS 2021 VS 20271.3.2 Hospitals1.3.3 Drugstores1.3.4 Others1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global Male Hypogonadism Therapy Market Perspective (2016-2027)2.2 Male Hypogonadism Therapy Growth Trends by Regions2.2.1 Male Hypogonadism Therapy Market Size by Regions: 2016 VS 2021 VS 20272.2.2 Male Hypogonadism Therapy Historic Market Share by Regions (2016-2021)2.2.3 Male Hypogonadism Therapy Forecasted Market Size by Regions (2022-2027)2.3 Male Hypogonadism Therapy Industry Dynamic2.3.1 Male Hypogonadism Therapy Market Trends2.3.2 Male Hypogonadism Therapy Market Drivers2.3.3 Male Hypogonadism Therapy Market Challenges2.3.4 Male Hypogonadism Therapy Market Restraints 3 Competition Landscape by Key Players3.1 Global Top Male Hypogonadism Therapy Players by Revenue3.1.1 Global Top Male Hypogonadism Therapy Players by Revenue (2016-2021)3.1.2 Global Male Hypogonadism Therapy Revenue Market Share by Players (2016-2021)3.2 Global Male Hypogonadism Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by Male Hypogonadism Therapy Revenue3.4 Global Male Hypogonadism Therapy Market Concentration Ratio3.4.1 Global Male Hypogonadism Therapy Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by Male Hypogonadism Therapy Revenue in 20203.5 Male Hypogonadism Therapy Key Players Head office and Area Served3.6 Key Players Male Hypogonadism Therapy Product Solution and Service3.7 Date of Enter into Male Hypogonadism Therapy Market3.8 Mergers & Acquisitions, Expansion Plans 4 Male Hypogonadism Therapy Breakdown Data by Type4.1 Global Male Hypogonadism Therapy Historic Market Size by Type (2016-2021)4.2 Global Male Hypogonadism Therapy Forecasted Market Size by Type (2022-2027) 5 Male Hypogonadism Therapy Breakdown Data by Application5.1 Global Male Hypogonadism Therapy Historic Market Size by Application (2016-2021)5.2 Global Male Hypogonadism Therapy Forecasted Market Size by Application (2022-2027) 6 North America6.1 North America Male Hypogonadism Therapy Market Size (2016-2027)6.2 North America Male Hypogonadism Therapy Market Size by Type6.2.1 North America Male Hypogonadism Therapy Market Size by Type (2016-2021)6.2.2 North America Male Hypogonadism Therapy Market Size by Type (2022-2027)6.2.3 North America Male Hypogonadism Therapy Market Size by Type (2016-2027)6.3 North America Male Hypogonadism Therapy Market Size by Application6.3.1 North America Male Hypogonadism Therapy Market Size by Application (2016-2021)6.3.2 North America Male Hypogonadism Therapy Market Size by Application (2022-2027)6.3.3 North America Male Hypogonadism Therapy Market Size by Application (2016-2027)6.4 North America Male Hypogonadism Therapy Market Size by Country6.4.1 North America Male Hypogonadism Therapy Market Size by Country (2016-2021)6.4.2 North America Male Hypogonadism Therapy Market Size by Country (2022-2027)6.4.3 United States6.4.3 Canada 7 Europe7.1 Europe Male Hypogonadism Therapy Market Size (2016-2027)7.2 Europe Male Hypogonadism Therapy Market Size by Type7.2.1 Europe Male Hypogonadism Therapy Market Size by Type (2016-2021)7.2.2 Europe Male Hypogonadism Therapy Market Size by Type (2022-2027)7.2.3 Europe Male Hypogonadism Therapy Market Size by Type (2016-2027)7.3 Europe Male Hypogonadism Therapy Market Size by Application7.3.1 Europe Male Hypogonadism Therapy Market Size by Application (2016-2021)7.3.2 Europe Male Hypogonadism Therapy Market Size by Application (2022-2027)7.3.3 Europe Male Hypogonadism Therapy Market Size by Application (2016-2027)7.4 Europe Male Hypogonadism Therapy Market Size by Country7.4.1 Europe Male Hypogonadism Therapy Market Size by Country (2016-2021)7.4.2 Europe Male Hypogonadism Therapy Market Size by Country (2022-2027)7.4.3 Germany7.4.4 France7.4.5 U.K.7.4.6 Italy7.4.7 Russia7.4.8 Nordic 8 Asia-Pacific8.1 Asia-Pacific Male Hypogonadism Therapy Market Size (2016-2027)8.2 Asia-Pacific Male Hypogonadism Therapy Market Size by Type8.2.1 Asia-Pacific Male Hypogonadism Therapy Market Size by Type (2016-2021)8.2.2 Asia-Pacific Male Hypogonadism Therapy Market Size by Type (2022-2027)8.2.3 Asia-Pacific Male Hypogonadism Therapy Market Size by Type (2016-2027)8.3 Asia-Pacific Male Hypogonadism Therapy Market Size by Application8.3.1 Asia-Pacific Male Hypogonadism Therapy Market Size by Application (2016-2021)8.3.2 Asia-Pacific Male Hypogonadism Therapy Market Size by Application (2022-2027)8.3.3 Asia-Pacific Male Hypogonadism Therapy Market Size by Application (2016-2027)8.4 Asia-Pacific Male Hypogonadism Therapy Market Size by Region8.4.1 Asia-Pacific Male Hypogonadism Therapy Market Size by Region (2016-2021)8.4.2 Asia-Pacific Male Hypogonadism Therapy Market Size by Region (2022-2027)8.4.3 China8.4.4 Japan8.4.5 South Korea8.4.6 Southeast Asia8.4.7 India8.4.8 Australia 9 Latin America9.1 Latin America Male Hypogonadism Therapy Market Size (2016-2027)9.2 Latin America Male Hypogonadism Therapy Market Size by Type9.2.1 Latin America Male Hypogonadism Therapy Market Size by Type (2016-2021)9.2.2 Latin America Male Hypogonadism Therapy Market Size by Type (2022-2027)9.2.3 Latin America Male Hypogonadism Therapy Market Size by Type (2016-2027)9.3 Latin America Male Hypogonadism Therapy Market Size by Application9.3.1 Latin America Male Hypogonadism Therapy Market Size by Application (2016-2021)9.3.2 Latin America Male Hypogonadism Therapy Market Size by Application (2022-2027)9.3.3 Latin America Male Hypogonadism Therapy Market Size by Application (2016-2027)9.4 Latin America Male Hypogonadism Therapy Market Size by Country9.4.1 Latin America Male Hypogonadism Therapy Market Size by Country (2016-2021)9.4.2 Latin America Male Hypogonadism Therapy Market Size by Country (2022-2027)9.4.3 Mexico9.4.4 Brazil 10 Middle East & Africa10.1 Middle East & Africa Male Hypogonadism Therapy Market Size (2016-2027)10.2 Middle East & Africa Male Hypogonadism Therapy Market Size by Type10.2.1 Middle East & Africa Male Hypogonadism Therapy Market Size by Type (2016-2021)10.2.2 Middle East & Africa Male Hypogonadism Therapy Market Size by Type (2022-2027)10.2.3 Middle East & Africa Male Hypogonadism Therapy Market Size by Type (2016-2027)10.3 Middle East & Africa Male Hypogonadism Therapy Market Size by Application10.3.1 Middle East & Africa Male Hypogonadism Therapy Market Size by Application (2016-2021)10.3.2 Middle East & Africa Male Hypogonadism Therapy Market Size by Application (2022-2027)10.3.3 Middle East & Africa Male Hypogonadism Therapy Market Size by Application (2016-2027)10.4 Middle East & Africa Male Hypogonadism Therapy Market Size by Country10.4.1 Middle East & Africa Male Hypogonadism Therapy Market Size by Country (2016-2021)10.4.2 Middle East & Africa Male Hypogonadism Therapy Market Size by Country (2022-2027)10.4.3 Turkey10.4.4 Saudi Arabia10.4.5 UAE 11 Key Players Profiles11.1 Eli Lilly11.1.1 Eli Lilly Company Details11.1.2 Eli Lilly Business Overview11.1.3 Eli Lilly Male Hypogonadism Therapy Introduction11.1.4 Eli Lilly Revenue in Male Hypogonadism Therapy Business (2016-2021)11.1.5 Eli Lilly Recent Development11.2 Pfizer11.2.1 Pfizer Company Details11.2.2 Pfizer Business Overview11.2.3 Pfizer Male Hypogonadism Therapy Introduction11.2.4 Pfizer Revenue in Male Hypogonadism Therapy Business (2016-2021)11.2.5 Pfizer Recent Development11.3 AbbVie11.3.1 AbbVie Company Details11.3.2 AbbVie Business Overview11.3.3 AbbVie Male Hypogonadism Therapy Introduction11.3.4 AbbVie Revenue in Male Hypogonadism Therapy Business (2016-2021)11.3.5 AbbVie Recent Development11.4 Novo Nordisk11.4.1 Novo Nordisk Company Details11.4.2 Novo Nordisk Business Overview11.4.3 Novo Nordisk Male Hypogonadism Therapy Introduction11.4.4 Novo Nordisk Revenue in Male Hypogonadism Therapy Business (2016-2021)11.4.5 Novo Nordisk Recent Development11.5 Merck KGaA11.5.1 Merck KGaA Company Details11.5.2 Merck KGaA Business Overview11.5.3 Merck KGaA Male Hypogonadism Therapy Introduction11.5.4 Merck KGaA Revenue in Male Hypogonadism Therapy Business (2016-2021)11.5.5 Merck KGaA Recent Development11.6 Mylan11.6.1 Mylan Company Details11.6.2 Mylan Business Overview11.6.3 Mylan Male Hypogonadism Therapy Introduction11.6.4 Mylan Revenue in Male Hypogonadism Therapy Business (2016-2021)11.6.5 Mylan Recent Development11.7 Bayer11.7.1 Bayer Company Details11.7.2 Bayer Business Overview11.7.3 Bayer Male Hypogonadism Therapy Introduction11.7.4 Bayer Revenue in Male Hypogonadism Therapy Business (2016-2021)11.7.5 Bayer Recent Development11.8 Teva11.8.1 Teva Company Details11.8.2 Teva Business Overview11.8.3 Teva Male Hypogonadism Therapy Introduction11.8.4 Teva Revenue in Male Hypogonadism Therapy Business (2016-2021)11.8.5 Teva Recent Development11.9 Novartis11.9.1 Novartis Company Details11.9.2 Novartis Business Overview11.9.3 Novartis Male Hypogonadism Therapy Introduction11.9.4 Novartis Revenue in Male Hypogonadism Therapy Business (2016-2021)11.9.5 Novartis Recent Development11.10 Abbott11.10.1 Abbott Company Details11.10.2 Abbott Business Overview11.10.3 Abbott Male Hypogonadism Therapy Introduction11.10.4 Abbott Revenue in Male Hypogonadism Therapy Business (2016-2021)11.10.5 Abbott Recent Development11.11 Roche11.11.1 Roche Company Details11.11.2 Roche Business Overview11.11.3 Roche Male Hypogonadism Therapy Introduction11.11.4 Roche Revenue in Male Hypogonadism Therapy Business (2016-2021)11.11.5 Roche Recent Development11.12 Endo International11.12.1 Endo International Company Details11.12.2 Endo International Business Overview11.12.3 Endo International Male Hypogonadism Therapy Introduction11.12.4 Endo International Revenue in Male Hypogonadism Therapy Business (2016-2021)11.12.5 Endo International Recent Development11.13 Ipsen11.13.1 Ipsen Company Details11.13.2 Ipsen Business Overview11.13.3 Ipsen Male Hypogonadism Therapy Introduction11.13.4 Ipsen Revenue in Male Hypogonadism Therapy Business (2016-2021)11.13.5 Ipsen Recent Development11.14 ANI Pharmaceuticals11.14.1 ANI Pharmaceuticals Company Details11.14.2 ANI Pharmaceuticals Business Overview11.14.3 ANI Pharmaceuticals Male Hypogonadism Therapy Introduction11.14.4 ANI Pharmaceuticals Revenue in Male Hypogonadism Therapy Business (2016-2021)11.14.5 ANI Pharmaceuticals Recent Development11.15 TherapeuticsMD11.15.1 TherapeuticsMD Company Details11.15.2 TherapeuticsMD Business Overview11.15.3 TherapeuticsMD Male Hypogonadism Therapy Introduction11.15.4 TherapeuticsMD Revenue in Male Hypogonadism Therapy Business (2016-2021)11.15.5 TherapeuticsMD Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Originally posted here:
Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,...

Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape – Jumbo News

The Global Male Hypogonadism Therapy Market report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Male Hypogonadism Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. The report provides key statistics on the market status of the Male Hypogonadism Therapy manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Report Highlights

Global Male Hypogonadism Therapy Market is expected to grow at a formidable rate and the market size will reach at remarkable number by 2025.The Global Male Hypogonadism Therapy market report also provides CAGR from 2020 to 2025.Key players in this market are Eli Lilly, Teva, Novo Nordisk, Pfizer, Bayer, AbbVie, Abbott, Mylan, Merck KGaA, Novartis, TherapeuticsMD, Roche, ANI Pharmaceuticals, Endo International, Ipsen, etc.

Complete report on Male Hypogonadism Therapy market spreads across 133 pages profiling companies and supported with tables and figures.

Our industry professionals are working relentlessly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Effect of COVID-19: Male Hypogonadism Therapy Market report investigate the effect of Coronavirus (COVID-19) on the Male Hypogonadism Therapy industry. Since December 2020, the COVID-19 infection spread to practically 180+ nations around the world with the World Health Organization pronouncing it a general wellbeing crisis. The worldwide effects of the Covid infection 2020 (COVID-19) are now beginning to be felt, and will essentially influence the Male Hypogonadism Therapy market in 2020

Get Sample Copy of Male Hypogonadism Therapy market 2020-2025 at: https://www.insidemarketreports.com/sample-request/14/650606/Male-Hypogonadism-Therapy

The major types mentioned in the report are Parenteral, Transdermal, Oral, Others,and the applications covered in the report are Hospitals, Drugstores, Others,.

The report provides insights in the following areas:

Market Size: Accurate market size and CAGR forecasts for the period 2020-2025

Also the mentioned Tables and Figure with required and significant statistics and insights are there in our report to give an all-round idea to our clients.

Purchase the copy of this report at: https://www.insidemarketreports.com/buy-now/14/650606/Male-Hypogonadism-Therapy/single

Purchase this Report now by availing up to 40% Discount and free consultation.Limited offer only.

Major Points from the Table of Contents

1 Male Hypogonadism Therapy Market Overview

2 Global Male Hypogonadism Therapy Market Competition by Manufacturers

3 Global Male Hypogonadism Therapy Capacity, Production, Revenue (Value) by Region)

4 Global Male Hypogonadism Therapy Supply (Production), Consumption, Export, Import by Region

5 Global Male Hypogonadism Therapy Production, Revenue (Value), Price Trend by Type

6 Global Male Hypogonadism Therapy Market Analysis by Application

7 Global Male Hypogonadism Therapy Manufacturers Profiles/Analysis

8 Male Hypogonadism Therapy Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Male Hypogonadism Therapy Market Forecast

13 Research Findings and Conclusion

14 Appendix

Report Customization

Global Male Hypogonadism Therapy Market, report can be customized according to your business requirements as we recognize what our clients want, we have extended 15% customization at no additional cost to all our clients for any of our syndicated reports.

In addition to customization of our reports, we also offer fully tailored research solutions to our clients in all industries we track.

About Inside Market Reports

Inside Market Reports provides the most comprehensive database of market intelligence reports. We provide quantified B2B research on 70,000 high growth emerging opportunities/threats which will impact 65% to 75% of Global Businesses, with 350+ Million easily actionable statistics with tables, figures and datasets (sales forecasts, market shares, production data).

Our Research Analysts have in-depth knowledge of various types of reports in their respective industries. They will help you refine search parameters, locate the full range of available reports, review the scope and methodology of the reports you choose, and give you informed and objective advice to ensure that you are making the right research purchase decision.

We constantly engage our market research partners to focus on the emerging market and technologies thus providing our clients with clarity insights and projections. The latest market research reports on industries, the developments and innovations have all the trends of well-known industries and prospects.

For all your Research needs, reach out to us at:

Email: [emailprotected]

Phone: +1-617-230-0741

See the original post here:
Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News

What is Harvey Prices disability Prader-Willi Syndrome? – The Sun

PRADER-WILLI syndrome is a rare genetic condition that affects one in 15,000 children in England.

While the condition itself isn't life-threatening, but its symptoms such as compulsive eating and weight gain can cause complications. Katie Price's eldest child Harvey, 18, was born with PWS and has now been administered into full-time care care so that he is able to be more independent life and learn new skills.

PWS is a genetic condition that can impact muscle tone, sexual development and the function of the nervous system.

As well as this, those with Prader-Willi syndrome are more likely to have learning difficulties.

Often, it also sparks a constant desire to eat food and a permanent feeling of hunger which leads to child obesity.

However, the syndrome is very rare, with the NHS estimating that it affects "no more than one in every 15,000 children born in England".

Those with PWS have a genetic defect on chromosome number 15.

In around 70 per cent of cases, some of the DNA information that's inherited from the father is missing, which is referred to as "paternal deletion".

Other cases occurwhen a child has two copies from their mother and none from their father.

The condition is obtained purely by chance, but those who have one child with PWS have a less than 1 per cent chance of the next one being affected.

Genetic tests are used to diagnose PWS.

Medical professionals will often carry out this check if they identify someone who is displaying the symptoms of Prader-Willi syndrome.

The NHS offers more detailed criteria for diagnosis on their website.

The Prader-Will Syndrome Association UK describes the medical characteristics of the condition as:

Hypotonia: weak muscle tone, and floppiness at birth. Hypogonadism: immature development of sexual organs and other sexual characteristics. Obesity: caused by excessive appetite and overeating (hyperphagia), and a decreased calorific requirement owing to low energy expenditure levels, although obesity is not normally a feature of those whose food intake is strictly controlled. Central nervous system and endocrine gland dysfunction: causing varying degrees of learning disability, short stature, hyperphagia, somnolence (excessive sleepiness), and poor emotional and social development.

3

As children with PWS can consume three to six times more food than other kids of the same age, there is a huge risk of obesity.

Consuming food compulsively can also lead to your stomach becoming abnormally expanded.

Young adults who have been diagnosed also run the risk of type 2 diabetes and heart failure if they don't control their eating.

As it currently stands, there is no cure for PWS.

Those who have been diagnosed with the condition are encouraged to take measures to lessen the severity of symptoms and associated problems.

Parents of child sufferers are asked to monitor any excessive eating and try to keep balanced and healthy meals on the menu.

3

Katie is raising awareness on new BBC show Katie Price: Harvey and Me on January 25 at 8.30pm, which documents her life as her sons carer.

Harvey Price is partially blind, autistic and has Prader-Willi syndrome and mum Katie has made the heart-wrenching decision to put Harvey into care.

She told The Sun: It breaks my heart. I dont want him to think Im just getting rid of him.

The move will gives him the best chance to forge an independent life and learn new skills.

In the past, Harvey's condition has led to major health concerns, as his condition makes him constantly feel hungry.

Katie had revealed doctors have warned that the battle to keep Harvey alive is critical as he could drop dead from a heart attack if he doesnt lose weight urgently.

She said: Its a cruel illness. He feels hungry all the time. Every time I feed him, its killing him.

Even though it makes him happy, its cruel of me to do it.

He needs to lose weight or hell end up dead. He doesnt deserve that. I dont want to lose him."

The reality star also says she's a "bloody good mum" and she hates it when people credit her exes for their "polite" kids.

3

When speaking to The Sun in a brutally honest chat ahead of new BBC documentary Katie Price: Harvey and Me, she declared: "I don't need to justify myself as a mother - I know I'm a bloody good mum.

"I can take my kids anywhere and wherever I've taken my kids, everyone is like, 'I can't believe how polite your kids are they're a pleasure to have', and that is down to me, their parenting and their dads as well."

She added: "The kids love coming to me, I'm completely different, I'm the laid back one.

"They get a bit of both, they get the strict parent and the easy going one where they can stay up later and watch a movie."

Harvey's homeWhat care is Katie Price's son Harvey going into?

PRICEY HOBBYBankrupt Katie Price spends 80 on scratch cards - but only wins 20

ABOUT HARVEYHow old is Katie Price's son Harvey Price and why is he going into care?

THE LIFE OF PRICEKatie Price family tree - all her children and marriages

'INSPIRING'Katie Price shows off new hair as This Morning viewers praise her mum skills

The former glamour model also spoke about Harvey's condition while filming her reality series My Crazy Life.

She said: "If he doesn't sort it out he will die, we've been told, because of his heart."

In a 2017 interview on Loose Women, Katie said:"He never knows when he's full up, he'll do anything he can to feed himself."

More:
What is Harvey Prices disability Prader-Willi Syndrome? - The Sun

The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% – NeighborWebSJ

Market Report Summary

Get Sample Copy of This Report -> Click Here

Read Full Press Release Below

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

https://neighborwebsj.com/

Read this article:
The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ

Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo…

The Global Androgen Replacement Therapy Market report provides a holistic evaluation of the market for the forecast period (20192025). The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market. These factors; the market dynamics involve the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Androgen Replacement Therapy Market study provides an outlook on the development of the market in terms of revenue throughout the prognosis period.

In order to present an executive-level model of the market and its future perspectives, the Androgen Replacement Therapy Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level. Furthermore, benefits related to application of testosterone replacement therapy include an increase in muscle tissue, overall surge in energy, and significant decrease in depression symptoms.

Major Players included in this report are as follows AbbVie, Inc., Allergan Plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc, Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, Dr. Reddys Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Par Pharmaceutical.

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/3787

Androgen Replacement Therapy Market: Regional analysis includes:

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Androgen Replacement Therapy Market.

Androgen Replacement Therapy Market scope

A basic summary of the competitive landscape A detailed breakdown of the regional expanse A short overview of the segmentation

Furthermore, this study will help our clients solve the following issues:

Cyclical dynamics We foresee dynamics of industries by using core analytical and unconventional market research approaches. Our clients use insights provided by us to maneuver themselves through market uncertainties and disruptions.

Identifying key cannibalizes Strong substitute of a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance.

Spotting emerging trends Our Ecosystem offering helps the client to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis helps clients to have an early mover advantage.

Interrelated opportunities This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in the real world.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/3787

Some of the Major Highlights of TOC covers:

Androgen Replacement Therapy Regional Market Analysis

Androgen Replacement Therapy Production by Regions Global Androgen Replacement Therapy Production by Regions Global Androgen Replacement Therapy Revenue by Regions Androgen Replacement Therapy Consumption by Regions

Androgen Replacement Therapy Segment Market Analysis (by Type)

Global Androgen Replacement Therapy Production by Type Global Androgen Replacement Therapy Revenue by Type Androgen Replacement Therapy Price by Type

Androgen Replacement Therapy Segment Market Analysis (by Application)

Global Androgen Replacement Therapy Consumption by Application Global Androgen Replacement Therapy Consumption Market Share by Application (2014-2019)

Androgen Replacement Therapy Major Manufacturers Analysis

Androgen Replacement Therapy Production Sites and Area Served Product Introduction, Application and Specification Androgen Replacement Therapy Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)Main Business and Markets Served

Key questions answered in the report:

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/3787

Key Benefits

Major countries in each region are mapped according to individual market revenue. Comprehensive analysis of factors that drive and restrict market growth is provided. The report includes an in-depth analysis of current research and clinical developments within the market. Key players and their key developments in recent years are listed.And More.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com

Read more:
Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo...

Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for…

Pune, India, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The global COVID-19 diagnostics market size is projected to reach USD 11.40 billion by 2027, exhibiting a CAGR of 7.9% during the forecast period. Uncontrolled spread of the coronavirus worldwide will be the major factor propelling the growth of this market, shares Fortune Business Insights in its report. According to Johns Hopkins University, global COVID-19 infections reached 100,000 in just 60 days, growing to 200,000 in the next 12-14 days, and the recent addition of 100,000 cases has taken only 3 days. The calculation of the spread of this disease is based on the estimation of the reproduction number or R Naught (Ro).

The UK Research and Innovation organization states that if the Ro goes above 1, exponential growth will be witnessed. As per a study published in the Journal of Clinical Medicine based on the virus transmission rate in Wuhan, the Ro was computed to be between 2.49 and 2.63. Such rapid transmission of the virus has surged the demand for coronavirus diagnostics tools and kits, which is boosting the growth of this market.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/covid-19-diagnostics-market-103291

Concerted Efforts towards Developing COVID Detection Tests to Accelerate Growth

With the COVID-19 pandemic showing no signs of abatement, medical and regulatory bodies are collaborating to encourage innovation and speed up research in developing coronavirus detection tools. For instance, in April 2020, the National Institutes of Health in the US announced the launch of Rapid Acceleration of Diagnostics (RADx) initiative with a funding of USD 1.5 billion to commercialize and widen the accessibility of COVID-19 testing.

Similarly, in June 2020, the US Food and Drug Administration (FDA) joined the COVID-19 Diagnostics Evidence Accelerator created by the Friends of Cancer Research and Reagan-Udall Foundation with the aim to evaluate the performance of PCR and antibody tests for COVID. Together, these and similar initiatives are expected to augment the COVID-19 diagnostics market growth throughout 2020.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/covid-19-diagnostics-market-103291

High Number of COVID-19 Cases to Give North America Leading Market Position

The United States is one of the worst-hit countries in the world by the coronavirus pandemic, with the number of cases as of June 2020 standing at 2.68 million and 129,000 deaths. In response, the US government is injecting more funds into medical research facilities to accelerate development of COVID-19 diagnostics and widen the testing net in the country. The regions market size in 2019 stood at USD 2.17 billion.

In Europe, the virus is spreading at a furious pace, with the UK, Italy, Spain, France, and Germany having the highest number of cases. Quick adoption of advanced detection tools in the region will enable it to expand its footprint in the COVID-19 diagnostics market share in the immediate future. Heavy investments by governments in Asia Pacific in the healthcare sector are expected to favor market growth in the region.

Regulatory Support to Novel Diagnostic Solutions to Encourage Innovation

The coronavirus is tightening its hold on the world and pharmaceuticals and governments are in a race against time to develop and launch quick and accurate diagnostic tests for this deadly virus. As a result, bodies such as the FDA are providing the necessary support to companies by removing unnecessary regulatory barriers, which is encouraging other players to innovate.

Quick Buy - COVID-19 Diagnostics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/103291

Industry Developments:

List of Key Players Covered in this Market Report:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/covid-19-diagnostics-market-103291

Table of Contents:

TOC Continued.!

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/covid-19-diagnostics-market-103291

Market Segmentations:

By Product

Instruments

Reagents & Kits

By Technology

Polymerase Chain Reaction (PCR)

Enzyme-linked Immunosorbent Assay (ELISA)

Point-of-care (POC)

Others

By Sample Type

Oropharyngeal & Nasopharyngeal Swabs

Blood

Urine

Others

By End User

Hospital & Clinics

Laboratories & Diagnostics Centers

Research Institutes

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

The Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Have a Look at Related Reports:

Neuromodulation Devices Market Share & Industry Analysis, By Product Type (Spinal Cord Stimulators (SCS), Deep Brain Stimulators (DBS), Vagus Nerve Stimulators (VNS), Sacral Nerve Stimulators (SNS), Transcranial Magnetic Stimulators (TMS)), By Type (Invasive, and Non-invasive), By Application (Pain Management, Neurological Disorders, Respiratory Disorders), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2019-2026

Polymerase Chain Reaction (PCR) Market Share & Industry Analysis, By Type (Standard PCR, Real-time PCR, and Digital PCR), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Academic & Research Organizations), and Regional Forecast, 2019-2026

Hunter Syndrome Treatment Market Share & Industry Analysis, By Treatment (Enzyme Replacement Therapy (ERT), and Others), By Route of Administration (Intravenous, and Intracerebroventricular (ICV)/ Intrathecal), By End User (Hospitals, Specialty Clinics and Others), and Regional Forecast, 2019-2026

Hormone Replacement Therapy (HRT) Market Share & Industry Analysis, By Therapy Type (Estrogen and Combinations Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, and Growth Hormone Deficiency), By Route of Administration (Oral, Transdermal, and Parenteral), By Distribution Channel (Hospital Pharmacies), and Regional Forecast, 2019-2026

Heart Valves Market Share & Industry Analysis, By Product Type (Replacement (Aortic, Mitral, and Others), and Repair), By Valve Type (Tissue Valve and Mechanical Valve), By Procedure (Surgical and Transcatheter), By End User (Hospitals, and Specialty Clinics & Others), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-covid-19-diagnostics-market-10100

Link:
Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for...

Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With…

KYZATREX has generated strong results in both safety and efficacy studies for KYZATREX for treatment of primary and secondary hypogonadism in men. Due to the robust results, especially regarding safety, Marius has requested a Priority Review that, if granted, would result in an anticipated six-month review period.

Submission of our first NDA is an important milestone, which is the culmination of over a decade of meticulous research and dedication and is just the beginning for Marius, as our pipeline will continue to advance research and development in this important therapeutic area that has a multitude of effects on our health system, said Himanshu H. Shah, Founder and Executive Chairman of Marius.

The NDA submission is based on efficacy and safety data from its pivotal study (NCT04467697) in which KYZATREX generated the most comprehensive ABPM data in its class. KYZATREX was well tolerated by participants, with greater than 96% of those subjects completing 90 days of treatment achieving average testosterone levels in the normal range in the pivotal Phase 3 study. The most common treatment-related treatment-emergent adverse event (TEAE) in the pooled Phase 3 studies was hypertension, while there were no serious TEAEs across the Phase 3 trials deemed related to the study drug.

We are extremely proud to have generated compelling efficacy and safety data in our Phase 3 trials, commented Dr. Om Dhingra, Co-Founder and CEO of Marius. We look forward to continuing to work collaboratively with the FDA on the review of our application, and if approved, KYZATREX has the potential to become the standard of care (SOC) for the treatment of primary and secondary hypogonadism globally.

Marius also intends to file a marketing authorization application (MAA) with the European Medicines Agency in the first half of 2022. For more information about Marius Pharmaceuticals and KYZATREX, visit mariuspharma.com.

About Testosterone & Hypogonadism

Hypogonadism, often referred to as testosterone deficiency, is a condition that occurs when the body does not produce adequate levels of testosterone. In addition to testosterones widely accepted role in sexual and reproductive function, it also has important roles in numerous other metabolic and inflammatory processes. In the U.S. there are at least six million symptomatic men suffering from hypogonadism, and over 100 million men globally. The resulting medical costs associated with men with untreated hypogonadism and related comorbidities are more than $25 billion in the U.S. alone.

Hypogonadism is also the most common cause of secondary osteoporosis in men. Beyond these diseases, hypogonadism is a common comorbidity in a broader set of conditions from Type-2 diabetes to Non-Alcoholic Steatohepatitis (NASH).

About KYZATREX

KYZATREX if approved, will represent a novel oral testosterone replacement therapy option for adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

The ReTUNE study was a multi-center, 12-month study across the U.S. that studied the safety and efficacy of KYZATREX in hypogonadal subjects (total testosterone 281 ng/dL). Efficacy was determined by number of subjects in the normal, eugonadal range after 90 days of treatment, including dose titrations, while safety was monitored for a further 9 months while on a steady dose. In addition to testosterone parameters, the study collected Patient Reported Outcomes (PROs), which showed statistically significant results both from baseline and against its comparator. A pivotal six-month Phase 3 study was conducted, in which subjects were monitored using ABPM, now considered the standard BP assessment by the FDA and clinical experts. An improved dose regimen was also used in the pivotal six-month Phase 3 study. The results of the Phase 3 studies will be published in leading medical journals and presented at national conferences during 2021.

The FDA has conditionally accepted KYZATREX as the trade name for this investigational drug. The safety and efficacy have not been fully evaluated by any regulatory authority.

About Marius Pharmaceuticals

Marius is a specialty pharmaceutical company focusing on treating conditions that are primarily associated with hypogonadism, commonly referred to as testosterone deficiency. The companys mission is to improve the functional lives of patients and reduce the risks of the downstream effects of endocrine imbalance by ensuring appropriate level of testosterone. For more information, please visit http://www.mariuspharma.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005046/en/

Go here to see the original:
Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With...

Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,…

Testosterone Replacement Therapy Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion of important industry like market trends, size, share, growth estimates are mentioned in the report.

The testosterone replacement therapy is used to improve sexual performance, accomplishing higher energy levels and building muscles. Testosterone replacement therapy has many benefits such as improved sexual desire, better blood sugar regulation, lowers bad cholesterol levels, decreased risk of diabetes, increased muscle mass and strength, improved brain function and cognitive ability, decreased body fat, improved ability to handle stress, increased confidence and a more positive mood, improved sleep and increased energy levels throughout the day. Testosterone replacement therapy has many side effects such as acne and oily skin, increased risk of heart attack, lower sperm count, which results in infertility, larger breasts, increased risk of blood clots and shrinkage of the testicles.

Get Discount up to 25% for Request Sample Copy ( 21 Dec, 2020 till 15 Jan, 2021):

https://www.alliedmarketresearch.com/request-sample/8759

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Testosterone replacement therapy includes substitution of testosterone hormone in male patients when they experience the ill effects of hypogonadism and lower testosterone level. The TRT drugs are accessible in six diverse forms that are gels, infusions, inserts, buccal glues and orals, which is influencing the market growth. Settled medicinal services and high use and interest for cutting edge TRT items are causing the growth. Increase in the awareness among people about testosterone replacement therapy is the factor to drive market. The high risks of infections like cardiovascular sickness and prostate disease related with testosterone substitution treatment will limit market development, which will restrain the growth.

Companies covered:

For Purchase Enquiry @https://www.alliedmarketresearch.com/purchase-enquiry/8759

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesUSA/Canada (Toll Free):+1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK:+44-845-528-1300Hong Kong:+852-301-84916India (Pune):+91-20-66346060Fax:+1(855)550-5975[emailprotected]Web:https://www.alliedmarketresearch.comFollow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

https://farmingsector.co.uk/

Go here to read the rest:
Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,...

The Anabolic Steroids Market to sharpen in the next decade – The Monitor

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

To remain ahead of your competitors, request for a sample[emailprotected]https://www.persistencemarketresearch.com/samples/29509

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

To receive Methodology request here @https://www.persistencemarketresearch.com/methodology/29509

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region. In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/29509

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

https://mmcthemonitor.com/

Go here to read the rest:
The Anabolic Steroids Market to sharpen in the next decade - The Monitor

Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report – DocWire News

This article was originally published here

Glob Reprod Health. 2020 Spring;5(1):e36. doi: 10.1097/grh.0000000000000036.

ABSTRACT

BACKGROUND: Multiple Sclerosis (MS) is an immune-mediated inflammatory disease characterized by demyelination of the CNS that affects women in their child-bearing years. There has been no absolute data to suggest infertility in this population; however, women with MS may exhibit decreased fertility due to various etiologies. Furthermore, their transition into menopause presents unique aspects in patient care.

METHODS: We report a case of a 38 year-old female with a diagnosis of MS with subsequent secondary amenorrhea and primary infertility. Multidisciplinary work-up with was consistent with hypothalamic hypogonadism secondary to MS affecting the pituitary stalk. She was treated for infertility in our clinic as well as management of her menopausal symptoms.

RESULTS: The patient conceived triplets after 2 cycles of ovarian stimulation with injectable gonadotropins and intrauterine insemination. She underwent fetal reduction to twins. After completion of childbearing, she was treated for menopausal symptoms with various hormonal therapies and ultimately remained on oral conjugated estrogens with no symptoms.

CONCLUSION: To our knowledge, this is the first report of infertility caused by suspected MS involvement of the pituitary stalk. In this patient population, infertility treatment can be successful with gonadotropins and alleviation of menopausal symptoms can be achieved with hormone replacement.

PMID:33354640 | PMC:PMC7751803 | DOI:10.1097/grh.0000000000000036

Here is the original post:
Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News

Male Hypogonadism Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2026 – Cheshire Media

The Male Hypogonadism Therapy market report provides a detailed analysis of the emerging trends, opportunities, and as well as the challenges in the market. This extensive report sheds light on the latest developments, market drivers, and competitive analysis to help the new entrants and emerging players to make crucial decisions.

Besides this, the market research report presents insights on consumer behavior, regulatory policies, and supply & demand scenario to provide a holistic view of the market. The primitive aim of the report is to represent the critical data and figures of the market concisely and layout top winning strategies to aid industry players to leverage their market position.

Get Free Sample Report + All Related Graphs & Charts: https://industrygrowthinsights.com/request-sample/?reportId=171163

The dedicated research team has included Porters Five Point Force analysis to tailor the Global Male Hypogonadism Therapy Market. They have conducted interviews with industry experts to provide accurate predictions and better insights in a detailed manner. The research report covers the latest advancements that have overhauled the market dynamics while examined the threats which has impacted the overall market.

Key Answers Captured in the Study are

Complete Purchase of Latest Version Global Male Hypogonadism Therapy Market Study with COVID-19 Impact Analysis: https://industrygrowthinsights.com/checkout/?reportId=171163

Important Features that are under offering & key highlights of the report:

Detailed overview of Male Hypogonadism Therapy

Changing market dynamics of the industry

In-depth market segmentation by Type, Application, etc.

Historical, current, and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Male Hypogonadism Therapy

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Male Hypogonadism Therapy performance

Market players information to sustain and enhance their footprint

Ask for the discount @ https://industrygrowthinsights.com/ask-for-discount/?reportId=171163

Research Objectives

To analyze and forecast the Worldwide Male Hypogonadism Therapy, in terms of value and volume.

Which segment has the potential to gain the highest market share?

To help decision-makers from a new offer perspective and benchmark existing marketing strategy.

Correlate cost structure historical data with key business segments.

Analyze marketing contribution and customer acquisition by up-selling and cross-selling.

Identifying Influencing factors keeping Worldwide Male Hypogonadism Therapy Intense, factored with periodic analysis of CR4 & CR8 concentration ratio & HHI Index.

Important Features that are under offering & key highlights of the report:

1) Does the study cover COVID-19 Impact Analysis and its effect on Growth %?

Yes, the overall industry has seen quite a big impact due to slowdown and shutdown in the production line & supply chain. The study covers a separate qualitative chapter on COVID-19 Impact analysis. Additionally, it also provides before and after the scenario of COVID-19 on sales growth & market size estimation to better analyze the exact scenario of the industry.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the report include:

Eli LillyPfizerAbbVieNovo NordiskMerck KGaAMylanBayerTevaNovartisAbbottRocheEndo InternationalIpsenANI PharmaceuticalsTherapeuticsMDMale Hypogonadism Therap

Usually, we follow NAICS Industry standards and validate company profile with product mapping to filter relevant Industry players, furthermore the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Can we add or profiled a new company as per our needs?

Yes, we can add or profile a new company as per client need in the report, provided it is available in our coverage list as mentioned in answer to Question 1 and after feasibility run, final confirmation will be provided by the research team checking the constraints related to the difficulty of survey.

4) Can we narrow the available business segments?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application or product type can be provided (If applicable) by Revenue Size or Volume*.

Male Hypogonadism Therapy market segmentation

The Study is segmented by following Product Type:

ParenteralTransdermalOralOthersMale Hypogonadism Therap

Major applications/end-users industry are as follows:

HospitalsDrugstoresOthers

5) Can a specific country of interest be added? What all regional segmentation covered?

Yes, Country-level splits can be modified in the study as per objectives. Currently, the research report gives special attention and focus on the following regions:

North America [United States, Canada, Mexico], Asia-Pacific [China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam], Europe [Germany, France, UK, Italy, Russia, Rest of Europe], South America [Brazil, Argentina, Rest of South America], Middle East & Africa [GCC Countries, Turkey, Egypt, South Africa, Rest of the Middle East & Africa]

** One country of specific interest can be included at no added cost. For inclusion of more regional segment quotes will vary.

Get on the call with our research analyst if you have any particular doubts before buying the report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171163

About Us:

Our reports are more than just research reports to us. They are tools that enable us to maintain long-term relationships with our clients whom we honor and cherish. Our clients business growth is integral for not only them but also us. This is what differentiates us from other market research companies.

At IGI, we provide our expertise and guideline for success. Our team of efficient and experienced researchers and consultants provide progressive market intelligence reports that are accurate, authentic, and in-depth. This empowers the clients to make well-informed decisions.

Moreover, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries including chemicals and materials, energy, automobile, healthcare, consumer goods, and technology. Our deep understanding of many business environments across industries such as those mentioned above allows us to deliver tailor-made reports.

Contact Us:

Alex MathewsHead of Business DevelopmentPhone No.: +1 909 545 6473Email [emailprotected] Website https://industrygrowthinsights.com Address 500 East E Street, Ontario, CA 91764, United States.

Read this article:
Male Hypogonadism Therapy Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2026 - Cheshire Media

Male Hypogonadism Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Astrazeneca Plc., Merck& Co. Inc.,…

Dataintelo, one of the worlds leading market research firms has rolled out a new report on Male Hypogonadism market. The report is integrated with crucial insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Global Male Hypogonadism Market to figure out and study market needs, market size, and competition. The report provides information about the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by key players.

The report also includes the impact of the ongoing global crisis i.e. COVID-19 on the Male Hypogonadism market and what the future holds for it. The pandemic of Coronavirus (COVID-19) has landed a major blow to every aspect of life globally. This has lead to various changes in market conditions. The swiftly transforming market scenario and initial and future assessment of the impact are covered in the report.

Request a sample Report of Male Hypogonadism Market: https://dataintelo.com/request-sample/?reportId=41372

The report is fabricated by tracking the market performance since 2015 and is one of the most detailed reports. It also covers data varying according to region and country. The insights in the report are easy to understand and include pictorial representations. These insights are also applicable in real-time scenarios. Components such as market drivers, restraints, challenges, and opportunities for Male Hypogonadism are explained in detail. Since the research team is tracking the data for the market from 2015, therefore any additional data requirement can be easily fulfilled.

The scope of the report has a wide spectrum extending from market scenarios to comparative pricing between major players, cost, and profit of the specified market regions. The numerical data is supported by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, and PESTLE analysis. The statistics are depicted in a graphical format for a clear picture of facts and figures.

The generated report is strongly based on primary research, interviews with top executives, news sources, and information insiders. Secondary research techniques are utilized for better understanding and clarity for data analysis.

The Male Hypogonadism Market is divided into the following segments to have a better understanding:

By Application:

Kallmann SyndromeKlinefelters SyndromePituitary DisordersOthers

By Type:

Testosterone Replacement TherapyGonadotropin-Releasing Hormones Therapy

By Geographical Regions:

Ask for Discount on Male Hypogonadism Market Report at: https://dataintelo.com/ask-for-discount/?reportId=41372

The Male Hypogonadism Market industry Analysis and Forecast 20192026 help clients with customized and syndicated reports holding key importance for professionals requiring data and market analytics. The report also calls for market-driven results providing feasibility studies for client requirements. Dataintelo promises qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are carried out ensuring client requirements with a thorough understanding of market capacities in the real-time scenario.

Some of the prominent companies that are covered in this report:

Key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. Following is the list of key players:

Astrazeneca Plc.Merck& Co. Inc.Laboratories GenevrierAllergan Plc.Endo International Plc.Ferring

*Note: Additional companies can be included on request

Reasons you should buy this report:

Dataintelo provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Customized Report and Inquiry for the Male Hypogonadism Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=41372

About US:

DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.

Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Read more:
Male Hypogonadism Market is Expected to Thrive at Impressive CAGR by 2026 & Top Key Players are Astrazeneca Plc., Merck& Co. Inc.,...

Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for M… – UroToday

Long-term androgen-deprivation therapy (ADT) is the standard of care in combination with radiotherapy (RT) in high-risk prostate cancer (PC), despite substantial toxicity from the resulting hypogonadism. We hypothesized that a combination of more potent but shorter-term androgen inhibition in men with intermediate or high-risk localized PC would synergize with definitive RT to provide short-term testosterone recovery and improve disease control.

This prospective phase 2 single arm trial enrolled men with low volume unfavorable intermediate or high-risk localized PC. Treatment included 6 months of ADT concurrent with abiraterone acetate plus prednisone once daily (AAP) and RT to prostate and seminal vesicles. The primary endpoint was the proportion of men with an undetectable PSA at 12-months; secondary objectives included biochemical progression-free survival (PFS), testosterone recovery, toxicity, and sexual/ hormonal quality-of-life.

We enrolled 37 men between January 2014 and August 2016, 45% of whom were high-risk .All patients had T1-2 disease and PSAs <20 ng/ml. Median follow-up is 37 months (95% CI: 35.7, 39.1).Treatment noted 32% grade 3 toxicities related to AAP, predominantly hypertension, with no >G4 toxicities. The rate of undetectable PSA at 12-months was 55% (95% CI 36-72%). With 46 months median follow-up, two of 37 patients developed PSA progression (36-month PFS 96%; 95% CI: 76%, 99%), and 81% of patients recovered testosterone with median time to recovery 9.2 months. Hormonal/sexual function declined at six months with subsequent improvement by 24 months.

The combination of RT and 6 months of ADT and AAP demonstrated acceptable toxicity and a high rate of testosterone recovery with restoration of QOL and excellent disease control in men with low volume intermediate or high-risk localized prostate cancer. Prospective comparative studies are justified.

International journal of radiation oncology, biology, physics. 2020 Nov 28 [Epub ahead of print]

Bridget F Koontz, Karen E Hoffman, Susan Halabi, Patrick Healy, Monika Anand, Daniel J George, Michael R Harrison, Tian Zhang, William R Berry, Paul G Corn, W Robert Lee, Andrew J Armstrong

Duke Cancer Institute Center for Prostate and Urologic Cancers Durham NC USA; Department of Radiation Oncology, Duke University, Durham NC USA. Electronic address: ., Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston TX USA., Duke Cancer Institute Center for Prostate and Urologic Cancers Durham NC USA; Department of Biostatistics and Bioinformatics, Duke University, Durham NC USA., Duke Cancer Institute Center for Prostate and Urologic Cancers Durham NC USA., Duke Cancer Institute Center for Prostate and Urologic Cancers Durham NC USA; Department of Medicine, Division of Medical Oncology, Duke University, Durham NC USA; Department of Surgery, Division of Urology, Duke University, Durham NC USA., Duke Cancer Institute Center for Prostate and Urologic Cancers Durham NC USA; Department of Medicine, Division of Medical Oncology, Duke University, Durham NC USA., Duke Cancer Institute Center for Prostate and Urologic Cancers Durham NC USA; Department of Radiation Oncology, Duke University, Durham NC USA., Duke Cancer Institute Center for Prostate and Urologic Cancers Durham NC USA; Department of Medicine, Division of Medical Oncology, Duke University, Durham NC USA; Department of Surgery, Division of Urology, Duke University, Durham NC USA; Department of Pharmacology and Cancer Biology, Duke University, Durham NC USA.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33259932

Read more here:
Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for M... - UroToday

Prader-Willi Syndrome Facts: Causes, Diagnosis, Treatments and Prognosis – Gilmore Health News

What is Prader-Willi Syndrome?

Prader-Willi syndrome is a rare genetic disorder caused by a defect of genes in the proximal arm of chromosome-15 which leads to life-threatening childhood obesity. It is associated with obesity, hypogonadism, intellectual deficits, small stature along with small hands, and feet.

A child with PraderWilli Syndrome

The first case of Prader-Willi syndrome was first described in a mentally impaired adolescent girl in 1887 by Langdon Down and was later described in medical literature in 1956 by Swiss doctors Andrea Prader, Alexis Labhart, and Heinrich Willi.

Presence of characteristic facial features like almond-shaped eyes, narrow bifrontal diameter, and the nasal bridge thin upper lip and downturned mouth. These features are noticed soon after birth.

Prader-Willi syndrome has been described worldwide and is a genetic disorder occurring in approximately 1 in every 15,000 live birth. It affects males and females equally, all races and ethnicities are equally susceptible.It is highly unlikely for parents to have more than one child with Prader-Willi syndrome.

PWS is caused due to abnormality in the expression of genes on Chromosome 15 specifically on the long arm of chromosome 15. This abnormality can be attributed to the following :

The defects seen in Prader-Willi syndrome is mostly attributed to hypothalamic disorder, which may explain some typical features of the syndrome like delayed growth and hyperphagia as the hypothalamus is the center for hormone production, growth, and hunger regulation.

Various studies have implied the role of Ghrelin in satiety defect and have found Ghrelin to be about 4-5 folds higher in people with PWS. (Ghrelin is a hormone produced by enteroendocrine cells and is also known as the Hunger Hormone)

Three sets of diagnostic criteria have been established for the diagnosis of Prader-Willi Syndrome. These are major, minor, and supportive.

These criteria though they dont have points, aid in the diagnosis of the disease.

Based on the guidelines established by Holmes et.al the diagnosis of Prader-Willi syndrome is highly likely in children younger than 3 years if they score 5 points with 3 of those coming from the major criteria.

In the case of children older than 3 years with Prader Willi syndrome is highly likely if they score 8 points with 4 from major criteria.

Magnetic Resource Imaging (MRI) of the head to assess hypopituitarism. The individuals with Prader-Willi syndrome are at risk of pathological fractures, however high degrees of pain tolerance in these patients make it necessary to diagnose fractures to prevent stiffness and malunion of fractures. DEXA Scan: To detect complications of osteoporosis. Scoliosis Film of the vertebra.

To reach the diagnosis of PWS we need to differentiate it from other diseases which may be causing similar features:

These conditions can be differentiated from PWS with the help of the DNA Methylation technique.

Apart from these, other genetic conditions are causing short stature and obesity which need to be ruled out:

There is no permanent cure for Prader-Willi syndrome currently, and the treatment of the syndrome requires a multidisciplinary approach from geneticists, endocrinologists, nutritionists, pulmonologists, neurologists to prevent complications from PWS.

The treatment is generally directed towards symptomatic relief and problem management.

The treatment plan needs to be continuously reassessed as the child grows older as it needs changes.

Early diagnosis and treatment of PWS can go a long way in improving their quality of life and help them reach their full potential.

Children with PWS require proper care apart from specific symptomatic treatments. Most children can benefit from the following:

Infants with PWS have low muscle tone consequentially they are unable to breastfeed properly. A pediatrician can help by recommending special feeding methods and prescribing high-calorie diets. Use of a Nasogastric tube may be required.

A proper diet low on calories but providing necessary nutrition is key in managing the weight of PWS in children. Supplemental vitamins and minerals are required for balanced growth. Proper diet complemented with increased physical activity help in weight management. The child should exercise for at least 60 minutes. The exercise routine should be broken down into multiple 5- 10 minute sessions in children having decreased energy levels.

As the desire for appetite in children with PWS is high, parents need to keep strict vigilance on their eating habits, there should be proper meal times, food should be kept out of their view and no extra feeding should be done.

Human growth hormone (HGH) treatment. An endocrinologist can help decide if the baby will benefit from HGH injections. In children with Prader-Willi syndrome, it helps in facilitating growth, decreasing body fat content, increasing muscle size, and muscle tone.

Sex hormone treatment. Children with PWS have a very low sex hormone level, requiring hormone replacement therapy (Testosterone for males; estrogen and progesterone for females). HRT begins as the child approaches puberty. Apart from raising hormonal levels, it helps also in preventing bone thinning. Orchidopexy may be required for Cryptorchidism (Undescended testis).

Treating sleep disturbances related to PWS can improve daytime sleepiness and behavioral issues in children.

Strict parenting is required to keep the behavior in check, especially concerning food, to prevent over-eating; a proper diet plan needs to be formulated. Calmness is required while dealing with children showing temper tantrums- the situation should be deflated as soon as possible by engaging the child in another topic. Medication may be required in some cases.

A psychologist or a psychiatric consultation may be required to address obsessive-compulsive disorders, skin picking, or mood disorders in children with PWS. The childs nails should be trimmed so that they do not develop cellulitis or other skin infections as a result of constant skin picking; any cases of skin infection should be treated immediately using antibiotics.

Most people with Prader-Willi syndrome will need specialized care and supervision throughout their lives for continuous consultation with the doctor is required to transition medical care to adulthood.

In cases of severe skin and pinching and psychoses, Anti-depressant or anti-psychotics can be helpful. SSRIs are the antidepressants of choice. These drugs however come with associated risks, so they are generally avoided below the age of 18. Cognitive-behavioral therapy may be required in some cases. It is a talking therapy that helps to change the way the patient thinks and behaves to modify unhealthy behavioral patterns.

Patients with Prader-Willi syndrome are at risk of developing the following complications:

People with PWS, who receive early treatment usually have a normal lifespan and can function in a group home setting, perform vocational work.

People with PWS, having normal IQ can expect to accomplish many of the things their peers do. However, each person requires lifelong support from the people involved to lead an independent life.

Complications due to morbid obesity and psychological issues can affect the quality of life and sometimes shorten life expectancy in patients with PWS.

Scientists worldwide have been working on finding a permanent cure and improving the quality of life by reducing complications for PWS by carrying out various researches worldwide.

Livoletide is being monitored as a drug to reduce ghrelin and consequently hyperphagia and obesity.

A randomized, double-blind placebo-controlled study conducted in 2019 in 47 adults who took 3-4 mg of Livoletide once a day for two weeks, reported a significant decrease in food-related behaviors as compared to people who were given a placebo.

https://www.nhs.uk/conditions/prader-willi-syndrome/

Read more from the original source:
Prader-Willi Syndrome Facts: Causes, Diagnosis, Treatments and Prognosis - Gilmore Health News

Male Hypogonadism HRT Treatment Market 2020-28 booming segments, latest trends and analysis with Merck & Co, Allergan, Endo International,…

Male hypogonadism usually is treated with testosterone replacement to return testosterone levels to normal. Testosterone can help counter the signs and symptoms of male Hypogonadism, such as decreased sexual desire, decreased energy, decreased facial and body hair, and loss of muscle mass and bone density.

The assessment report offers an exquisite point of view on the Global Male Hypogonadism HRT Treatment business sector business area including bit of the general business, esteem, pay, advancement rate, creation by type. It arranges and dismember the parts as for type, area, and application. Also, it on a very basic level revolves around the application by inspecting the advancement rate and use of every individual application. The Global business sector business part scene and driving producer offers genuine scene and market headway status including the chart of every individual market players.

Request for a sample report here @ https://www.reportconsultant.com/request_sample.php?id=78172

Top Key Players:

Merck & Co. Inc., Laboratories Genevrier, Allergan Plc., Astrazeneca Plc., Endo International Plc., Ferring, AbbVie Inc., Eli Lilly and Company Ltd., Finox Biotech, Teva Pharmaceutical Industries Ltd., Bayer AG, and IBSA Institut Biochimque.

It gives an information in regards to Porters Five Forces including substitutes, likely contestants, purchasers, industry contenders, and providers with certified data for comprehension the worldwide Male Hypogonadism HRT Treatment business sector. Besides, it offers nitty gritty information of sellers including the profile, determinations of item, deals, applications, yearly execution in the business, speculations, acquisitions and mergers, advertise size, income, piece of the pie, and thats only the tip of the iceberg.

Market Report Segment: Available form

Market Report Segment: by region

Besides, it offers full-house information of sellers including the profile, details of item, applications, yearly execution in the business, deals, income, ventures, acquisitions and mergers, advertise size, piece of the pie, and the sky is the limit from there. The report has made the worldwide business sector report with an inclusion of point by point diagram of the worldwide Male Hypogonadism HRT Treatment industry including worldwide creation deals, worldwide income, and CAGR.

The Male Hypogonadism HRT Treatment business sector report conveys an inside and out investigation of market size, nation level market size, locale, division advertise development, piece of the overall industry, deals examination, esteem chain improvement, showcase players, the serious scene, late turns of events, vital market development investigation, exchange guidelines, openings examination, item dispatches, mechanical advancements, and zone commercial center extending. The Male Hypogonadism HRT Treatment business sector reports conveys the information about market rivalry between sellers through local division of business sectors regarding income age potential, business openings, request and flexibly over the anticipated period.

Get reports for upto 40% discount @ https://www.reportconsultant.com/ask_for_discount.php?id=78172

The exploration report has drafted the report with the contributions of value, creation type, obtaining and mergers, Male Hypogonadism HRT Treatment business sector size, piece of the overall industry, deals investigation, esteem chain streamlining, exchange guidelines, mechanical developments, openings examination, and market players. The report presents the modern chain investigation, downstream purchasers, and crude material sources alongside the precise experiences of Male Hypogonadism HRT Treatment business sector elements.

At the end, of the Global Male Hypogonadism HRT Treatment Market Professional Survey Report 2020 includes:- Methodology, Analyst Introduction and Statistics Supply. At long last, the examination contains Male Hypogonadism HRT Treatment SWOT investigation, venture partialness examination, speculation incorporate innovative work propensity examination.

About Us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative business in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered business all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the global futuristic market.

Contact us:

Riaana Singh

(Report Consultant)

sales@reportconsultant.com

http://www.reportconsultant.com

Read more from the original source:
Male Hypogonadism HRT Treatment Market 2020-28 booming segments, latest trends and analysis with Merck & Co, Allergan, Endo International,...

Archives